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A B S T R A C T
Transdermal drug delivery offers a number of advantages for the patient, due not only its non-invasive
and convenient nature, but also factors such as avoidance of ﬁrst pass metabolism and prevention of
gastrointestinal degradation. It has been demonstrated that microneedle arrays can increase the number
of compounds amenable to transdermal delivery by penetrating the skin’s protective barrier, the stratum
corneum, and creating a pathway for drug permeation to the dermal tissue below. Microneedles have
been extensively investigated in recent decades for drug and vaccine delivery as well as minimally
invasive patient monitoring/diagnosis. This review focuses on a range of critically important aspects of
microneedle technology, namely their material composition, manufacturing techniques, methods of
evaluation and commercial translation to the clinic for patient beneﬁt and economic return. Microneedle
research and development is ﬁnally now at the stage where commercialisation is a realistic possibility.
However, progress is still required in the areas of scaled-up manufacture and regulatory approval.
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1. Introduction
For thousands of years, people have placed chemical agents on the
skin surface, whether for healing, protective or cosmetic reasons.
Historically, the skin had been viewed as an impermeable barrier to
exogenous chemicals [1]. Topical drug therapy traditionally involved
application of medicinal substances or drug-laden formulations to
the skin only when its barrier had been compromised by disease or
infection. In such cases, a direct route for drug absorption into viable
skin was open. New possibilities for systemic delivery of medicines
began to be realised once it was understood that intact skin is not a
completely impermeable barrier. During the early 20th century, the
increased skin permeability of more lipophilic agents was reported.
By 1919, the barrier properties of the skin had been attributed
speciﬁcally to the upper layers [2]. Subsequently, Scheuplein et al.
investigated in vitro skin permeability to a wide range of substances
[3]. They modelled skin as a three-layered laminate composed of the
stratum corneum, epidermis and dermis, with drug permeation
driven by Fickian diffusion. By separating the stratum corneum from
the lower layers of the skin, this outermost 10–15 mm of tissue was
determined to be the principal barrier to drug absorption. By the
1960s, systemic delivery of drugs applied topically to the intact
stratum corneum began to attract attention.
The ﬁrst transdermal system for systemic delivery—a three-day
patch that delivers scopolamine to treat motion sickness—was
approved for use in the United States in 1979 [4]. A decade later,
nicotine patches became the ﬁrst transdermal blockbuster, raising
the proﬁle of transdermal delivery in medicine and for the public in
general. Advantages of this approach include:
 Prevention of gastrointestinal degradation and food-related
inconsistency in absorption
 Avoidance of ﬁrst pass hepatic metabolism
 Possibility for improved bioavailability
 Maintenance of relatively constant plasma concentrations for up
to 7 days with the same patch
 Elimination of pain, discomfort, risk of infection and poor
compliance associated with injections
Recently,thetransdermalroutehasviedwithoral treatmentasthe
most successful innovative research area in drug delivery. Currently,
81 activeclinical trials, studyingapplications rangingfrom vaccines to
drug delivery to biofeedback loops, are ongoing. The worldwide
transdermal patch market approaches $31.5 billion, yet is based on
less than 20 drugs [5]. This rather limited number of transdermal
drugs is attributed to the skin’s excellent barrier function. Before
being taken up by blood vessels in the upper papillary dermis, and
prior to entering the systemic circulation, substances permeating the
skin must cross the stratum corneum and the viable epidermis
[6]. There are three possible pathways leading to the capillary
network: through hair follicles with associated sebaceous glands, via
sweat ducts, or across continuous stratum corneum between these
appendages [7]. As the fractional appendageal area available for
transport is only about 0.1%, this route usually contributes negligibly
to steady state drug ﬂux [7]. The intact stratum corneum thus provides
the main barrier to exogenous substances, including drugs [6]. The
corneocytes of hydrated keratin are analogous to ‘‘bricks’’, embedded
in a ‘‘mortar’’ composed of highly organised, multiple lipid bilayers of
ceramides, fatty acids, cholesterol and its esters [7]. These bilayers
form regions of semicrystalline gel and liquid crystal domains. Most
molecules penetrate through skin via this intercellular microroute.
Facilitation of drug penetration through the stratum corneum may
involve by-pass or reversible disruption of its elegant molecular
architecture [7]. The ideal properties of a molecule penetrating intact
stratum corneum well are [7]:
 Molecular mass less than 600 Da, when the diffusion coefﬁcient
in SC tends to be high
 Log P value between 1 and 3
 High, but balanced, SC/vehicle partition coefﬁcient, such that the
drug can diffuse out of the vehicle, partition into, and move
across, the SC without becoming sequestered within it
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 Low melting point, correlating with good solubility, as predicted
by ideal solubility theory
Clearly, many drug substances do not do not satisfy these
criteria. Those with Log P values below 1 are too hydrophilic to
efﬁciently penetrate the stratum corneum by passive diffusion
[7]. Those with Log P values greater than 3, which are the primary
focus of the present application, are so hydrophobic that they
become entrapped within the intercellular lipids of the stratum
corneum and partition into the essentially aqueous environment of
the viable epidermis below at such low rates that therapeutic
plasma concentrations cannot be achieved [7]. Chemical penetra-
tion enhancers have no appreciable value in increasing transder-
mal ﬂux of such compounds. Alternative enhancement strategies
have, to date, focussed strongly on increasing transdermal delivery
of hydrophilic drugs. This is understandable, given the ever-
increasing number of biotechnology-derived protein and peptide
molecules with therapeutic potential that have to be dosed
parenterally due to gastrointestinal breakdown, poor absorption
through biological membranes, rapid plasma clearance, peculiar
dose-response curves and immunogenicity [7]. Accordingly, ion-
tophoresis has been used to drive hydrophilic drugs through hair
follicles and sweat glands, while electroporation, sonophoresis and
suction, laser and thermal ablation create transient aqueous pores
in the stratum corneum [7]. In practical and economic terms,
however, these approaches suffer from considerable limitations.
2. Microneedles: characteristics, history and delivery strategies
2.1. Characteristics and history
Microneedle arrays (MN) are minimally invasive devices that
by-pass the SC barrier, thus accessing the skin microcirculation and
achieving systemic delivery by the transdermal route. MN (50–
900 mm in height, up to 2000 MN cm2) [8] in various geometries
and materials (silicon, metal, polymer) are produced using
microfabrication techniques [7,9]. MN are applied to the skin
surface and painlessly pierce the epidermis, creating microscopic
aqueous pores through which drugs diffuse to the dermal
microcirculation [7,10]. MN are long enough to penetrate to the
dermis, but are short and narrow enough to avoid stimulation of
dermal nerves or puncture of dermal blood vessels [7,10]. No
reports on development of skin infection exist and we have shown
that MN can be reproducibly inserted into skin by patients without
additional applicator devices [11]. Solid MN puncture skin prior to
application of a drug-loaded patch or are pre-coated with drug
prior to insertion. Hollow bore microneedles allow diffusion or
pressure-driven ﬂow of drugs through a central lumen, while
polymeric MN release their drug payload as they dissolve or
biodegrade in the viable skin layers [12]. In vivo studies using MN
have demonstrated delivery of oligonucleotides, hormones,
reduction of blood glucose levels from insulin delivery, increase
of skin transfection with DNA and elicitation of immune responses
from delivery of DNA and protein antigens [10,12,13].
MN were ﬁrst conceptualised in the 1970s [14], but it was not
until the late 1990s when they became the subject of signiﬁcant
research due to advancements in microfabrication technology that
enabled their manufacture [15]. In the ﬁrst published paper on MN,
Henry et al. described the use of silicon MN to facilitate the delivery
of calcein (model drug) across excised human skin in vitro. Since
then, these devices have been extensively investigated [7,10,
12,16]. In 2004, it was suggested that MN arrays could be used to
permit transdermal transport of macromolecules and possibly
supramolecular complexes and microparticles [10]. Over the last
decade, extensive research has been carried out on MN technology
using a wide variety of materials and MN designs [7]. Moreover,
a range of fabrication methods have been developed [9]. Five
different types of MN designs are described in the literature [12],
namely solid, coated, hollow, dissolvable and hydrogel-forming
MNs.
2.2. Delivery strategies
Solid MNs are normally employed in the so-called ‘poke with
patch’ approach [10]. Solid MN are applied to the skin and then
removed, creating transient aqueous microchannels are created in
the stratum corneum. Subsequently, a conventional drug formula-
tion (transdermal patch, solution, cream or gel) is applied, creating
an external drug reservoir (Fig. 1A). Permeation through these
microchannels occurs via passive diffusion. The main limitation of
this approach is the requirement for a two-step application
process, which may lead to practicality issues for patients. The
materials used to produce solid MN are typically silicon [17,18],
metals and polymers [19].
Coated MNs are prepared by coating solid MN with a drug
formulation prior to skin application. After insertion of coated MN
arrays into the skin, the coated drug formulation will be dissolved
and deposited in the skin (Fig. 1B). This delivery strategy is
typically referred to as ‘coat and poke’ [10]. Coated MNs have been
employed for the rapid cutaneous delivery of macromolecules,
such as vaccines, proteins, peptides and DNA to the skin [12]. This
type of MN allows a simple one-step application process, but its
main limitation is the restricted amount of drug that can be coated
onto the ﬁnite surface area of the MN structures. Accordingly, the
use of coated MNs is restricted to potent molecules/drugs. Various
techniques have been developed to efﬁciently coat the individual
MN shafts in MN arrays [20,20–22].
The third type of MN are dissolving MNs. They are made by
micro-moulding soluble matrices, generally a biocompatible
polymer or sugar, including the active substance [7]. The skin
insertion of the array is followed by dissolution of the MNs tips
upon contact with skin interstitial ﬂuid. The drug cargo is then
released over time (Fig. 1C). The release kinetics of the drug
depends upon the constituent polymers’ dissolution rate.
Therefore, controlled drug delivery is achievable by adjusting
the polymeric composition of the MN array, or by modiﬁcation of
the MN fabrication process. Dissolving MNs present numerous
advantages. The principal beneﬁt is the low cost of polymeric
materials and their relatively facile fabrication by micro-
moulding processes at ambient temperatures, which should
allow for straightforward industrial mass production. Various
materials, including poly(vinyl alcohol) (PVA), poly(vinylpyrro-
lidone) (PVP), dextran, carboxymethyl cellulose (CMC), chondroi-
tin sulfate and a sugars have all been used to produce this type of
MN array [23]. Importantly, the use of water-soluble materials
eliminates the potential risk of leaving biohazardous sharp waste
in the skin. Moreover, safe MN disposal is facilitated, since the MN
are, by deﬁnition, self-disabling [4,24]. On the other hand, the
main limitation of this type of systems is the deposition of
polymer in skin, possibly making these systems undesirable if
they are likely to be used on an ongoing basis [25]. Biodegradable
MN can also be included in this category. This type of MNs is
produced using biodegradable polymers, including poly(lactic
acid), chitosan, poly(glycolic acid), or poly(lactide-co-glycolide)
(PLGA) to form the matrix. After insertion they degrade, rather
than dissolve in the skin, releasing their cargo. Accordingly,
release could possibly be sustained for months by choosing the
appropriate polymer [26]. Since biodegradation typically pro-
duces small molecules by hydrolysis, polymer is not deposited in
skin indeﬁnitely. However, such MN typically require high
temperatures during manufacture, which may damage biomolec-
ular cargoes.
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Hollow MNs allows the delivery of a particular medication into
the skin via the injection of a ﬂuid formulation through the inserted
hollow needles (Fig. 1D). This type of MNs allows continuous
delivery of molecules across the skin through the MN bore using
different methods: diffusion or pressure- or electrically driven
ﬂow. Such systems are possibly capable of delivering larger
amounts of drug substances in comparison to solid, coated and
dissolving MNs [27]. Hollow MNs are made from a range of
materials, including silicon and metal [27–29], glass [30], polymers
[31] and ceramic [32]. The main limitations of hollow MNs are the
potential for clogging of the needle openings with tissue during
skin insertion [33] and the ﬂow resistance, due to dense dermal
tissue compressed around the MN tips during insertion [34]. The
ﬁrst limitation can possibly be overcome by using an alternative
design to locate the bore-opening at the side of the MN tip
[35]. Partial needle retraction following insertion may also
enhance ﬂuid infusion, due to relaxation of the compressed tissue
around the tips [30]. However, use of liquid drug formulations
will require a suitable, possibly complex, reservoir and liquid
formulations are notoriously unstable, particularly at the elevated
ambient temperatures found in the developing world.
A relatively new type of MN arrays are prepared from hydrogel-
forming matrices. Such systems were ﬁrst described recently by
Donnelly et al. [8,36]. This novel strategy involves integrated
systems consisting of crosslinked drug-free polymeric MN
projecting from a solid baseplate to which a patch-type drug
reservoir is attached. After application of the MN array to the skin,
the inserted needle tips rapidly take up interstitial ﬂuid from
the tissue, thus inducing diffusion of the drug from the patch
through the swollen microprojections (Fig. 1E). These systems
are manufactured using aqueous blends of speciﬁc polymeric
materials, namely poly(methyl vinyl ether-co-maleic acid) cross-
linked by esteriﬁcation using poly(ethyleneglycol)
[8,25,37,38]. Garland et al. showed that drug delivery can be
tailored by modulating the crosslink density of the hydrogel matrix
[39]. Importantly, hydrogel-forming MNs are removed intact from
skin, leaving no measurable polymer residue behind. However,
they are sufﬁciently softened to preclude reinsertion, thus further
reducing the risk of transmission of infection [40]. Other polymers
that can be used to prepare hydrogel-forming MNs are chitosan,
PLGA and poly(vinyl alcohol) [41,42]. With these alternative
polymer systems, however, the drug is included inside the
hydrogel-forming MN patch rather than in an external patch
[42], thus limiting the quantity of drug that can be delivered.
3. Material types and biocompatibility
3.1. Material selection and properties
3.1.1. Silicon
Silicon was the material selected for the ﬁrst MNs used for drug
delivery because the technology needed to manufacture micron or
submicron structures only became available with the advent of
industrial high-precision microelectronics tools during the 1990s
[7,9,15,33,43–45]. Silicon has proved very useful in manufacture of
microstructures and microelectromechanical systems (MEMS) for
a number of reasons [45]. Its main advantage is that there is much
ﬂexibility in the processes that can be used to shape it, meaning
that microstructures in a variety of desirable shapes and sizes can
be readily produced. Using monocrystalline or polycrystalline
silicon allows tailoring of speciﬁc solutions to a broad range of
requirements. Moreover, silicon offers many attractive physical
Fig. 1. A schematic representation of ﬁve different MN types used to facilitate drug delivery transdermally. (A) Solid MNs for increasing the permeability of a drug formulation
by creating micro-holes across the skin. (B) Coated MNs for rapid dissolution of the coated drug into the skin. (C) Dissolvable MNs for rapid or controlled release of the drug
incorporated within the microneedles. (D) Hollow MNs used to puncture the skin and enable release of a liquid drug following active infusion or diffusion of the formulation
through the needle bores. (E) Hydrogel-forming MNs take up interstitial ﬂuids from the tissue, inducing diffusion of the drug located in a patch through the swollen
microprojections.
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properties, making it an attractive and versatile material. Finally,
the manufacturing methods that exist for silicon substrates are
precise and capable of batch production that reduce costs [43].
Silicon is an anisotropic crystalline material, the material
properties of which depend upon orientation relative to the crystal
lattice, yielding different elastic moduli, ranging from 50 to
180 GPa [46]. Therefore, in some cases, silicon can present an
elastic modulus comparable to metals used for orthopaedic
implants (see Section 3.1.2). Their considerable mechanical
strength allows silicon MNs to successfully pierce the skin
[15,47,48], facilitating transdermal drug delivery [17,33]. Silicon
has been used extensively in manufacture of MNs with multiples
shapes, heights and densities [49–51]. The three main types of MN
that have been prepared using this material are: solid [15,17,
18,45,52], hollow [27,33] and coated MNs [53] (Fig. 2A–C). The
main limitations of silicon are its high cost, elaborate fabrication,
long fabrication times and complex multi-step processing
[43,54]. Furthermore, there have been concerns with the
biocompatibility of silicon [55,56]. Due to the brittle nature of
the material [56], some silicon MN could become fractured in the
skin [57] and this may raise health concerns. Biocompatibility is
discussed further in Section 3.2. Numerous studies have been
carried out to evaluate the reliability of silicon MNs in terms of
their failure forces and investigation of the failure mechanism of
the needle tips [47,48,57] (Fig. 2D and E).
3.1.2. Metals
Metals have been in medical use for decades. Classic examples
are stainless steel (e.g. hypodermic needles) or titanium (e.g.
implants and prostheses). Since conventional exploitation of these
materials in production of medical devices, MN production should
not present additional safety issues, thereby smoothing the way
towards regulatory approval. The main metals used in productions
of MNs are stainless-steel, titanium, palladium, palladium-cobalt
alloys and nickel [58]. In addition to their good biocompatibility,
such metals possess good mechanical properties. Young’s moduli
of the stainless steel used medical implants, SUS316L stainless
steel, is around 180 GPa [59]. Young’s moduli of Ti (pure titanium)
and its alloys are generally smaller than those of stainless steels.
For example, Ti and its alloy, Ti-6Al-4V ELI, are common materials
in implants devices and have Young’s moduli around 110 GPa
[59]. A comparison of the mechanical properties of these types of
metals can be found in Table 1. The elastic moduli of these are
comparable to the highest possible for silicon (up to 180 GPa).
Moreover, metals have higher fracture toughness and similar
Fig. 2. SEM images of (A) solid, (B) hollow and (C) coated silicon MN arrays. (D) Force–displacement graph for silicon MN compression test showing discontinuities
characteristic of structural failure. (E) SEM images of damage to needle after application of 0.3 N and 0.5 N compressive loads to the needle tip. lc is the distance from the
needle apex to the intersection of the longitudinal axis of the MN and the broken plane. In this case, lc is 14 mm.
Source: Reproduced with permission of: [17,27,33,53,57].
Table 1
Strengths of materials used to make microneedles.
Material Young’s
Modulus
(GPa)
Ultimate tensile
strength (MPa)
Silicon 110 7000
Glass 85 50
Nickel 214 586
Palladium 117 186
Platinum 147 117
Titanium 110 241
Stainless steel 200 1000
Ormocer1 17 30
PMMA 3 170
Maltose 31.1 –
SU-8 3 –
Source: Data obtained from: [166].
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values of yield strength (Fig. 3). Consequently, metals are possibly
a more suitable material to silicon in MN manufacture.
Stainless steel was the ﬁrst metal used in production of MN
arrays. Most metal MNs have been obtained by manually pressing
the tips of the smallest available stainless steel hypodermic
needles (30/31 G) through a supporting material of deﬁned
thickness [7,60]. Less commonly, stainless steel MNs in a variety
of designs have been produced using microfabrication technology
[60–64,21] (Fig. 4A).
A good alternative to stainless steel is titanium. Despite
possessing less robust mechanical properties to stainless-steel,
this material is certainly strong enough for biomedical applications
[59]. Titanium MNs have been produced, mainly as bio-sensors
[65,66] and as transdermal delivery systems [67] (Figure 4B).
3.1.3. Ceramics
Another material that has been used to produce MNs is ceramic.
Mainly they are produced using a micromolding technique by
ceramic slurry cast into micromould [9] (see Section 4.1.2).
Micromolding techniques offer the advantage of being able to
develop device production as a low cost process, due to the
potential for up-scaling the technology [9].
The main type of ceramic used to produce MN has been alumina
(Al2O3) [68,69] (Fig. 4C). This material presents some advantages,
principally chemical resistance. The Al2O3 molecule is one of the
most stable oxides, because of the high energetic ionic and
covalent bonds between Al and O atoms [70]. These strong bonds
leave the ceramic unaffected by corrosion or adverse environmen-
tal conditions [70]. Under compression, alumina showed good
resistance (Table 1), but under tensile stress it is shown to be brittle
[70]. Table 1 shows lower strength resistance to tension than other
materials, such as metals. Additionally, Bystrova et al. showed that
Al2O3 MNs can be fractured during manual skin insertion
[68]. Al2O3 MNs may be employed as a drug-coated solid MN
array, following the ‘coat and poke’ (see Section 2.2) approach for
release into the skin. However, due to the porosity of alumina, this
type of ceramic MN, this type of MNs also holds a deﬁned volume
of active for controlled release through its open pore volume
[69]. Other types of biocompatible ceramic used to prepare MNs
are calcium sulfate dihydrate [Gypsum (CaSO42H2O)] and calcium
phosphate dihydrate [Brushite (CaHPO42H2O)] [71] (Fig. 4D).
These materials have been used before as drug delivering bone
cements, so they present good mechanical and drug loading
properties [72,73]. Additionally to pure ceramic MN arrays, during
Fig. 3. Strength versus toughness graphs for different types of materials.
Source: Adapted from: www.materials.eng.cam.ac.uk/mpsite (Lovatt A.M., Shercliff H.R. and Withers P.J. (2000), ‘‘Material selection and processing’’); data courtesy of Granta
Design Ltd, Cambridge, UK.
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recent years, MN arrays have also been fabricated using an organic-
ceramic hybrid material called Ormocer1 [74,75]. This type of
material contains organically modiﬁed silicon alkoxides and
organic monomers forming a three-dimensional network
[74]. An interesting characteristic of this type of materials is that
its properties can be adjusted by varying the composition, the
synthesis parameters tailoring the properties of the ﬁnal material
[76].
3.1.4. Silica glass
Silica glass is an alternative to the materials described above.
Glass MNs can be quickly produced in various geometries for
small-scale laboratory use. This material is physiologically inert,
allows easy visualisation of ﬂuid ﬂow and, ﬁnally, can be fabricated
with dimensions similar to those of microfabricated MNs
[30,77,78] (Fig. 5A and B). Glass MN described in the literature
are hollow in nature and have typically been used to bypass the
stratum corneum and inject medicines [30,77]. Borosilicate glass
presents lower values of elastic moduli (64 GPa) [79], making this
material more elastic. However, silica glass is a brittle material and,
as can be seen in Fig. 3, silicon and silica glass present similar
fracture toughness. Fabrication of glass MNs is not time efﬁcient,
since it is typically performed by hand [80]. Glass MNs are still used
today, but only for experimental purposes and are not viable for
commercial use in drug delivery [30].
3.1.5. Carbohydrates
MN can be prepared easily by moulding hot melts/slurries of
carbohydrate materials using silicon or metal MNs as master
templates [81–85]. Drugs to be delivered are added to the mixture
before casting the formulation into the moulds. Such MNs should
dissolve upon skin insertion to release their drug payload
[81]. Carbohydrates are good alternatives to the previously
described materials, as they are cheap and, additionally, safe for
the human health [85].
Maltose has been one of the most common sugars used to
prepare MN arrays [82,83,86] (Fig. 5C–E). Other sugars, such as
trehalose, sucrose, mannitol, xylitol and galactose have also been
studied [81,87]. The mechanical properties of these MN arrays
have not been extensively investigated. Galactose MN presented
signiﬁcant reductions in MN height when relatively small forces
were applied to them against an aluminium block. Nevertheless,
this was not observed during their relatively facile insertion into
heat-stripped epidermis [81]. Consequently, this type of MNs
seems to have enough strength to pierce the skin and deliver their
cargos [82,86]. However this type of MN presents a range of
disadvantages. Donnelly et al. reported inherent problems in the
processing, storage, and use of MN arrays prepared from sugars
[81]. The main drawback of this type of MN is that the need for
thermal treatment during the manufacturing limits the number of
compounds that can be loaded in the arrays. Additionally, during
the release process, partially dissolved sugar sealed the MN-
induced holes, thus limiting drug delivery. Finally, storage under
conditions of temperature and relative humidity adversely affect
this type of MN, as can be seen in Fig. 5E. Such difﬁculties are likely
to preclude commercial development or clinical application of
carbohydrate-based MN arrays. In addition to simple sugars,
polysaccharides have also been used to prepare MN arrays. As they
Fig. 4. (A) Different types of stainless-steel MNs: (a) hollow stainless-steel 4  4 MN array, (b) higher magniﬁcation of a single hollow stainless-steel needle, (c) solid stainless-
steel 4  4 MN array and (d) a higher magniﬁcation of a single solid needle. (B) Scanning electron microscopy of titanium microneedle array coated with 80 mg of
desmopressin per array. (a) Bar = 1 mm; (b–d) bar = 50 mm. Scanning electron micrographs of (C) alumina ceramic, (Da-Dc) gypsum and (Dd-Df) brushite.
Source: Reproduced with permission of: [63,67,69,71].
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are macromolecules, they will be included in the next section (see
Section 3.1.6).
3.1.6. Polymers
Polymeric materials are promising alternatives to the previ-
ously described materials for MN production. Some polymers and
polysaccharides are drawing increasing attentions because of their
excellent biocompatibility, biodegradability, low toxicity,
strength/toughness and low cost [7,26]. In general, polymers
present lower strength than silicon, metals, ceramic and glass, but
better toughness, than glass and ceramics (Fig. 3 and Table 1).
A wide variety of macromolecular materials have been
efﬁciently used to fabricate MNs: poly(methyl methacrylate)
(PMMA) [88–90], PLA [91], PGA [80], PLGA [92], poly(carbonate)
[93], cyclic-oleﬁn copolymer [31,94], poly(vinylpyrrolidone) (PVP)
[95,96], poly(vinylalcohol) PVA [96], polystyrene (PS) [97],
poly(methyl vinyl ether-co-maleic anhydride) [8,98], poly(methyl
vinyl ether-co-maleic acid) [25], SU-8 photoresist [99] and
polysaccharides [84,100–102]. Fig. 6 shows the structures of some
of these polymers. Polymers are used mainly in production of
dissolving/biodegradable and hydrogel-forming MN arrays. Nev-
ertheless, to some extent, there are some studies using polymers
for the production of solid [19,89], hollow [49,90] and coated MN
arrays [103].
Dissolving/biodegradable polymeric MN arrays have been
produced using different types of polymers [26]. The dissolution/
biodegradation process (depending upon the composition of the MN
material) releases the drug molecules from the matrix for local or
systemic delivery (Fig. 7A) [7]. Macromolecular dissolving MN
systems are prepared with polysaccharides (Fig. 7B). The main ones
are carboxymethlycellulose, amylopectin, dextrin, hydroxypropyl
cellulose, alginate and hyaluronic acid [26,102]. MN prepared using
these macromolecules present sufﬁcient mechanical properties to
penetrate the skin and deliver their cargos (model molecules,
lysozyme and insulin) [84,100,101]. In addition to polysaccharides,
synthetic polymers have also been used to prepare dissolving MN
arrays. The main ones are poly(methyl vinyl ether-co-maleic
anhydride) (Gantrez AN-1391) [37,98,104,105], PVP and PVA
[96]. MN prepared using Gantez AN-1391 are strong enough to
bypass the stratum corneum. Due to the plastic nature of the polymer,
this type of MN s are able to resist compression forces up to 0.7 N/
needle without breaking. Additionally, MN prepared using PVP and
PVA possess sufﬁcient strength to pierce the skin and deliver their
cargos [96]. On the other hand, biodegradable MN arrays are
produced mainly using PLA, chitosan, PGA or PLGA [26]. Biodegrad-
able MN have been used to deliver different types of therapeutics,
from small molecules to macromolecules or nanoparticles across the
skin [26].
In addition to dissolving/biodegradable MN, the other main
type of polymeric MN arrays are swelling or hydrogel-forming MN
arrays [41]. This type of MN arrays provides drug release as a result
of the polymer swelling when absorbing body ﬂuid, leaving no
measurable polymer residuals after removal from skin (Fig. 7C–E)
[41]. The needle tips swell in skin to produce conduits. The drug
can diffuse from a patch-type drug reservoir to the dermal
microcirculation using these conduits, thus allowing prolonged
transdermal drug administration [7]. The mechanical properties of
these materials allows skin insertion and mechanical resistance to
fracture when dry, making this type of hydrogel a good candidate
for hydrogel-forming MNs manufacture [7]. The swelling of this
type of device can be modiﬁed by adding NaHCO3, a pore forming
agent [106]. Besides polyanhydride type polymers, only mixtures
Fig. 5. (A) Front and (B) side views of a representative hollow, glass microneedle. (C) Scanning electron micrograph image of 500 mm long solid maltose microneedles shown
opposite to a tip of a 26 G hypodermic needle, (D) in an individual array and (E) magniﬁed view that show the radius of the tip. (F) Inﬂuence of the storage conditions for
galactose MN arrays. (a) Light micrograph of galactose microneedles upon preparation. (b) Scanning electron micrographs of the same array. (c) Light micrograph of galactose
microneedles after storage at a relative humidity of 43% for 1 h and (d) 6 h. (e) Light micrograph of galactose microneedles after storage at a relative humidity of 75% for 1 h. (f)
Light micrograph of galactose microneedles after storage at a relative humidity of 0% for 3 weeks.
Source: Reproduced with permission of: [77,81,86].
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of polysaccharides (dextran, gelat) and PVA have been reported to
be used successfully to produce hydrogel-forming MN arrays for
drug delivery (Fig. 7B) [41,42,102]. Yang et al. reported the use of
PVA, dextran and CMC to prepare hydrogel-forming MN arrays
[42]. In this case, crosslinking was carried out by a freeze–thaw
process. Using a similar process, Demir et al. prepared swelling MN
arrays by crosslinking PVA and gelatin [102].
3.2. Biocompatibility and biodegradability of microneedle materials
As detailed above, MN arrays pierce the stratum corneum
barrier, exposing the MN tips to the viable skin tissue. Therefore, it
is mandatory that the materials selected for production of MN are
biocompatible. The most important factor that differentiates a
biocompatible material from any other type of material is its ability
to exist in contact with tissues of the human body without causing
an unacceptable degree of harm to such tissues. To the best of our
knowledge, the skin biocompatibility of all MN materials has not
been extensively evaluated.
3.2.1. Biocompatibility of silicon and silica glass
As described above, silicon and silica glass are brittle materials
and a realistic concern about MN produced with such materials is
the possibility of a breakage of the tips once they are inserted. Any
broken pieces of such MNs will most likely be extravasated within
four weeks, during the normal turnover of the epidermis
[107]. Importantly, though there have been notable reports of
silicon- and glass-related granulomas [108,109].
As silicon is one of the main MEMS materials, the biocompati-
bility of silicon has been examined during the last 20 years in a
wide number of studies [110]. There are different studies assessing
the biocompatibility of MEMS devices made of silicon for brain and
subcutaneous implants [111–113]. Bayliss et al. showed that
nanocrystalline silicon does ‘‘not exhibit signiﬁcant cytotoxicity’’
[114]. On the contrary, other research works described some
biocompatibility problems. Moreover, there are reports describing
formation of granulomas [109] in subcutaneous tissue and an in
vitro study demonstrated the formation of nodules on periodontal
ligament ﬁbroblasts when using a silicon-bearing bioglass. This
phenomenon has been attributed to silicon release from the glass
[115]. In conclusion, the biocompatibility of silicon is still
uncertain. However, there is a silicon MN-based product already
on the market, Micronjet1 (see Section 5.2.5) that received FDA
clearance in 2010 [12]. This system consists of silicon MNs
attached to a syringe and they are not inserted inside the skin for
prolonged periods of time. As detailed above, silica glass can cause
granulomas in the skin [108], but borosilicate glass apparently
seems to be biocompatible for cortical implants [116]. Therefore,
the use of silicon and silica glass for MN manufacture should be
carefully studied, as there is currently not sufﬁcient evidence of the
biocompatibility of these materials.
3.2.2. Biocompatibility of ceramics
Ceramics have been used for repair and replacement parts of
musculoskeletal systems during recent decades due to their good
biocompatibility and high strength [117]. The precise type of
ceramic used will, obviously, inﬂuence its biocompatibility.
Alumina has been used for nearly 25 years in orthopaedic
materials for bone and dental implants [117]. Therefore, its
biocompatibility has been extensively studied [118–120]. Despite
exhibiting good biocompatibility, some studies showed that
alumina is not totally stable under physiological conditions and
there is a risk of aluminium release from long-term bone implants
[121]. However, this phenomena is not observed for short term
implants [121], so MN arrays made of alumina should not present
signiﬁcant problems. Calcium-phosphate compounds used as bone
substitute materials already have a ﬁrm place in clinical
applications [122,123]. This type of ceramics is considered
biocompatible, bioactive in the sense of osteoconduction and
bioresorbable [124]. Additionally, calcium sulphates present
similar characteristics [125]. Finally, a range of studies showed
that Ormocer1 presents good biocompatibility and is safe for use
as a biomedical material [32,126,127]. Ovsianikov et al. demon-
strated that this material does not adversely affect growth of
human epidermal keratinocytes, a major cellular component of the
skin [32].
3.2.3. Biocompatibility of metals
Metals used in production of MNs are normally biocompatible
and have a dominant role to play in structural biomaterials used in
Fig. 6. Chemical structure of some of the polymers used to produce MN.
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reconstructive surgery, especially orthopaedics, with more recent
uses in non-osseous tissues, such as blood vessels [128].
Stainless steel is the generic name for a number of iron-based
alloys that contain a high percentage (11–30 wt%) of chromium
and varying amounts of nickel [128]. The properties and
biocompatibility of stainless steel are affected by its composition
[128]. The most common surgical stainless steel is 316L. In general,
316L stainless steel shows relatively good biocompatibility, but to
a less satisfactory extent to other metals, such as titanium alloys,
due to its greater corrosion rates [128]. However, the uses of MN do
not typically require long application times, so corrosion is unlikely
to present signiﬁcant problems. The times of application of metal
MN arrays will most likely be similar to those of stainless steel
hypodermic needles that are considered biocompatible and,
therefore, widely used [129].
Compared with stainless steel, titanium alloys have proven to be
superior in terms of biocompatibility. This is mainly due to their
excellent corrosion resistance [128]. Mutagenicity is not signiﬁcant,
as determined by in vitro mutation assays, indicating that titanium
alloys are safe for humans and animals [128]. However, ﬁrst
generation titanium alloys have been reported to cause allergic
reactions in the human body [130]. Second generation titanium
alloys have been developed and investigated with great interest.
They are considered to be relatively safe. So far, there is a lack of long-
term clinical application data and follow-up reports on the
biocompatibility of these titanium alloys [128]. Palladium and
platinum present good biocompatibility [131,132]. However, they
have been investigated to a much lesser extent in production of MNs.
On the other hand, caution should be used when employing nickel as
a material for fabricating MNs. Nickel is known to be carcinogenic
and adverse allergic reactions have also been problematic in the past
with nickel-containing biomaterials [133].
3.2.4. Biocompatibility and biodegradability of carbohydrates
Natural sugars are an important ingredient of many drug
delivery systems, as they are safe for use in humans [85]. Maltose is
Fig. 7. (A) False colour optical coherence tomography images of the in vitro dissolution proﬁle of Gantrez-AN 1391microneedles in porcine skin over a 3-h period. (B) SEM
photographs of parts from 10  10 MN arrays made of: (a) alginat, (b–c) hydroxypropyl cellulose, (d) cross-linked PVA-gelatin, and (e) chitosan. (C) Digital photographs of
equilibrium swollen hydrogels (with initial dimensions of 1 cm  1 cm) prepared from aqueous blends of 15% w/w PMVE/MA and 7.5% w/w PEG 10,000 containing (a) 0%, (b)
1%, (c) 2%, and (d) 5% w/w of NaHCO3 showing changes in respective dimensions. (D) Gantrez S-97
1MN before and after swelling for 3 hs in PBS pH 7.4. (E) Representative
optical coherence tomography images of hydrogel forming MN array before and after insertion into neonatal porcine skin for a period of 24 h. Scale bar represents a length of
300 mm.
Source: Reproduced with permission of: [25,102,105,106].
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the main sugar used in the production of carbohydrate-based MN
arrays. This sugar has been extensively used in different FDA-
approved parenteral formulations [134]. Besides maltose, galactose
is used in approved parenteral formulations [134]. Understandably,
certain products containing maltose or galactose can produce
interferences with blood glucose monitoring [134]. While maltose
and galactose may be considered safe for MN production, this
interference issue should be taken into account. Sucrose, mannitol,
trehalose and xylitol can all be found in a diverse range of parenteral
formulations as cryoprotectants, stabilisation agents or as paren-
teral nutrition products [135,136]. In addition to simple sugars,
polysaccharides have been widely researched as biomaterials for a
variety of biomedical applications, including in drug delivery and
regenerative medicine [137]. Due to their chemical similarity with
human extracellular matrix components, these polymers are
recognised and accepted by the body [137]. If absorbed, poly-
saccharides can be eliminated by glomerular ﬁltration in the kidney,
provided they are below the glomerular threshold [138]. The
molecular weight, as well as the size and the shape of the polymer
has a major inﬂuence on its excretion and the rate of glomerular
ﬁltration. This phenomenon also apples to non-degradable synthetic
polymers. Cellulose derivatives, such as carboxymethyl cellulose
and hydroxypropyl cellulose are biocompatible and biodegradable
[139,140] and have been employed in drug delivery formulations
and as components of therapies for preventing post-surgical
adhesions [141]. Chitosan has proven to be biocompatible and is
biodegraded into non-toxic residues [142]. The polysaccharide
chitosan is mainly degraded by lysozyme through the hydrolysis of
the acetylated residues [138]. However, the rate of its degradation is
strongly related to the molecular mass of the polymer and its
deacetylation degree. Due to their biocompatibility, alginates have
been extensively used for microencapsulation and for medical
applications, such as tissue reparation, and in wound dressings
[143]. Although alginates have been extensively investigated as
biomaterials, one of their main disadvantages is their inability to
undergo enzymatic degradation by mammals. There are, however, a
number of ways to prepare alginate-based materials to increase
their biodegradability [144]. Hyaluronic acid (HA) has been
extensively studied in drug-delivery applications. A variety of
commercially available preparations of HA derivatives and cross-
linked HA materials have been developed for drug delivery
[145]. This material can be considered biocompatible and biode-
gradable [145], since HA can be degraded within the body by free
radicals found in the extracellular matrix, followed by endocytosis.
Moreover, it can also undergo digestion by lysosomal enzymes to
form mono- and di-saccharides, which can be further converted
into ammonia, carbon dioxide and water via the Krebs cycle
[144]. Starch-based polymers, such as amylopectin, are not an
obvious choice for biomedical applications, as normally they are
biocompatible but not easily biodegradable in human tissue
[146]. The main reason for this is that the cellular energy storage
polymer in humans is glycogen and not starch. Dextrins have not
been extensively-used for biomedical applications. However, it has
been proved that they are biocompatible and non-immunogenic,
being degradable by a-amylases and undergoing renal clearance,
thus avoiding tissue accumulation [147,148].
3.2.5. Biocompatibility and biodegradability of polymers
The majority of polymers used to produce MNs are biocompat-
ible. In addition to their biocompatibility, some of the described
polymers are biodegradable. This property makes them interesting
materials to use for MN production, since they will degrade after
piercing the skin [92].
PC and PMMA have been extensively used for medical purposes
and are known to be biocompatible [149–151]. PMMA has been
used for a wide variety of medical applications, such as in bone
cements and intraocular lenses [150]. PC, on the other hand, has
been used for medical apparatus, such as syringes, artery cannulas,
as blood ﬁlter housings and for dental brackets [151]. In terms of
stability, PMMA is not biodegradable [152], while PC can be
biodegraded, releasing Bisphenol-A (BPA), the main raw material
used in the production of the aromatic poly(carbonate) [153–
155]. The release of BPA can be problematic, as this compound has
been reported to induce hormone-related adverse effects [153].
PS polymers have been used for in vitro applications, including
containers for a variety of liquids, cells and bacteria, and in vivo
applications, such as in microspheres used as carriers of drugs and
magnetic particles. Nevertheless, the biocompatibility of these
materials is limited, so PS is typically not used where biocompati-
bility is a requirement [156,157]. Nevertheless Vesel et al.
demonstrated that the treatment of PS with non-equilibrium
oxygen plasma improve the biocompatibility of the material [156].
PVA and PVP are commonly used in biomedical applications
[158,159]. PVA is used as a biomaterial, due to its biocompatible,
nontoxic and non-carcinogenic nature, swelling properties and
bioadhesive characteristics [158]. PVP is a hydrophilic, biocom-
patible polymer [159] and it is used in many biomedical
applications, presenting an extremely low cytotoxicity, due to
its water solubility [160]. PVP is biodegradable but to a lesser
extent than PVA [160]. Additionally, PVP is a common excipient
used in pharmaceutical formulations [135]. Another type of
polymer with a wide variety of biomedical uses is SU-8. This
epoxy-based polymer has been used in fabrication of microelec-
trodes for measuring electrical impedance in living tissues,
monitoring neural spikes and for intraocular pressure sensing
[161]. Nemani et al. studied the biocompatibility of this type of
material in vitro and in vivo, demonstrating the suitability of SU-8
as an implant material, supporting cell viability [161].
Cyclic oleﬁn copolymers are currently receiving much attention
for their structural strength, optical clarity and biocompatibility
[162]. Moreover, they are suitable materials for tissue engineering
[163]. The biocompatibility of this type of material can be affected,
in vitro at least, by modifying its surface [163].
PLA, PGA and PLGA are the most commonly used aliphatic
polyesters in MN production. There is a wide variety of studies
using such polymers in production of drug delivery systems,
showing their good biocompatibility [164,165]. In addition to
being biocompatible, the aliphatic polyesters are biodegradable
(Fig. 8). This property makes them appealing materials to use for
MNs, since they will degrade after piercing the skin [92]. The
degradation rates of polyesters can be controlled, for example, by
varying the ratio of PGA to PLA in the PLGA copolymer [164,166].
Poly(methyl vinyl ether-co-maleic anhydride) and its acid form
(Gantrez1 type co-polymers) have been extensively used as
thickening and suspending agent for medicinal agents used in
topical salves and ointments [167]. Additionally, it has been used for
over 60 years as the bioadhesive in denture adhesives [167]. Due to
its low toxicity it has been used in development of nanoparticle-
based oral drug delivery systems [168–171]. The biocompatibility of
these types of polymers has not been extensively studied.
Nevertheless, some research works have demonstrated the in vitro
biocompatibility of hydrogels prepared using Gantrez1 co-polymers
[172,173]. Additionally, McCrudden et al. performed in vitro
biocompatibility and in vivo rat skin tolerance experiments using
dissolving MN arrays, showing no adverse effects [104].
4. Microneedles design, manufacture and mechanical testing
4.1. Manufacturing technologies
In order to produce MN devices, investigators have used a
plethora of manufacturing methods, including chemical isotropic
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etching, injection moulding, reactive ion-etching, surface/bulk
micromachining, polysilicon micromolding, lithography-electro-
forming-replication, laser-drilling and two-photon polymerisation
[7,9]. Furthermore, MNs have been produced in a wide range of
designs [7,10,12]. The two basic designs are in-plane and out-of-
plane MNs. Some designs combine in-plane and out-of-plane MN.
For in-plane designs, the MNs are parallel to the fabrication
surface, while for out-of-plane designs the MNs are perpendicular
to the fabrication surface [174]. In the following sections, different
methods used for MN fabrication are described.
4.1.1. Fabrication of silicon microneedles
Silicon MNs are produced mainly using MEMS technology. This
type of technology utilises diverse tools and methodologies to
create small 3D structures, with dimensions ranging from sub-
centimetre to sub-micrometre. Originally, this technology was
developed for production of integrated circuits. A MEMS process
involves a series of sequential operations. The three basic
techniques in MEMS technology are: application of a patterned
mask on top of a ﬁlm by photolithographic imaging; deposition of
thin ﬁlms of material on a substrate; and etching the ﬁlms
selectively to the mask [175,176].
4.1.1.1. Lithography and etching. The majority of processes in
microelectronics and micromachining fabrication starts with
lithography. This technique is used to transfer a master pattern
onto the surface of a substrate (e.g. silicon wafer). For this purpose,
this surface is previously coated with a photosensitive material by
selective exposure to a radiation source (e.g. UV light). Indeed, the
most widely used type of lithography is photolithography. In
general, the subsequent steps are involved in the mask transfer
onto the photosensitive-coated substrate (Fig. 9) [176]. The ﬁrst
Fig. 8. Hydrolysis of PLGA, PGA and PLA.
Fig. 9. Sequential processes in the transfer of a pattern to the substrate surface: (a) Si wafer; (b) Si wafer with oxide coating; (c) spin-coated photoresistive material; (d) mask
guided UV light exposure on the photoresistive material; (e) development process to remove the soluble resist material; (f) etching of SiO2 ﬁlm; and (g) photoresist removal.
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step, using a silicon wafer as a substrate, is to form a thin layer of
oxide by heating between 900 and 1150 8C in the presence of steam
or humidiﬁed oxygen. Subsequently, a thin layer of an organic
polymer sensible to UV radiation, known as photosensitive/
photoresist or resist material, is coated onto the oxide surface of
the silicon wafer using a spin coating process (spun between
1500 and 8000 rpm) to yield a resist of deﬁned thickness
[176]. After the spin coating step, the solvent present in the resist
layer is removed by heating between 75 and 100 8C for 10 min. In
addition to solvent evaporation, this process promotes adherence
of the resist layer to the wafer. Once the solvent is removed, the
resist-coated wafers are exposed to illumination through a mask
(normally UV radiation between 150 and 500 nm). This procedure
allows an almost perfect transfer of the mask image onto the resist-
coated wafers [175]. The radiation treatment prompts a chemical
reaction in the exposed regions of the resist. After this reaction, the
solubility of the exposed resist is altered. Thereafter, this region of
the resist can be dissolved using a suitable solvent. This process can
be either by wet (using solvents) or dry (using vapour phase or
plasma) developments [177]. Then, an oxygen-plasma treatment,
called de-scumming, is used to remove the unwanted resist left
behind. Finally, and before moving to the next process, the wafers
are post-baked with two purposes: to remove the residual
developing solvents and to improve adhesion between resist
and substrate interfaces.
Two main types of resists can be used: positive resists and
negative resists. In the ﬁrst one, the chemical bonds within the
resists are weakened when exposed to UV light and, subsequently,
the exposed resists become more soluble in the development
solutions. In negative resists, these chemical bonds are strength-
ened when exposed to UV radiation. Normally, the mask used in
photolithography is typically an optically ﬂat glass or quartz plate,
transparent to near UV, with a metal absorber layer. Additionally,
there are other technological alternatives to create a desired
pattern on a substrate, such as X-ray and charged-particle beam
lithography [175,176].
Following lithography, it is necessary to etch the thin oxide
layer previously deposited and/or the substrate itself (Fig. 9). In
order to perform wet etching, the wafer is immersed in a liquid
bath containing a chemical etchant to remove the desired material.
The two main wet etching techniques are isotropic and anisotropic
etching. The ﬁrst type, attacks the material (e.g. oxide, nitride,
aluminium, polysilicon, gold or silicon) at the same rate, and in all
directions. They remove material horizontally under the etch
mask. In contrast, anisotropic etchants attack the material
(normally silicon wafer) at different rates, depending upon the
directions. This process allows production of more controlled
shapes. The crystal planes in silicon limit anisotropic wet etching.
The etchants used for isotropic etching are normally hydroﬂuoric
and nitric acids, in combination with either methanol or water
[178]. The chemical agents used for anisotropic wet etching are
potassium hydroxide (KOH) and tetramethyl ammonium hydrox-
ide (TMAH) [179]. A critical aspect that must be considered is that
the mask should not dissolve, or at least etch at a much slower rate
than the material to be etched [175]. Conversely, dry etching is
carried out at low pressure using inert or reactive gases. There are
two main types of dry etching: reactive ion etching (RIE) and ion-
beam milling (IBM). The ﬁrst one is a chemic al process, while the
latter involves physical treatment. In RIE, a plasma of reactive ions
is created in a chamber and these ions are accelerated towards the
material to be etched. In the case of IBM, inert ions are accelerated
from a source to physically remove the material to be etched.
When the entire substrate is showered with energetic ions, it is
called showered-IBM (SIBM) and when the ions are focused to a
spot of the material, it is called focused-IBM (FIBM) [175]. In order
to create high aspect ratio (height-to-width ratio) structures, a
deep RIE (DRIE) process can be used. This etching process is used in
combination with chemical vapour deposition (ﬁlm forming
process) and it is called the BOSCH process.
4.1.1.2. Silicon MN produced using a lithography and/or etching
process. As detailed above, Henry et al. were the ﬁrst to publish on
solid silicon MN fabrication by following a dry etch process (RIE
with a chromium mask) [15]. Since then, numerous research
groups have used both wet- and dry-etching processes in
fabrication of a wide variety of solid silicon MNs. Wilke et al.
fabricated solid silicon MNs using a wet-etch process. A standard
P-type (doped with boron or gallium) silicon wafer was deposited
with a 300 A˚ oxide layer and a 1000 A˚ layer of nitride.
Subsequently, this double layer was etched using a plasma-etch
to form 280 mm high MN arrays (with aspect ratio 3:2) [50]. The
major disadvantage of this method of fabrication was the
limitation of MN height and density.
Using the dry-etching technique, Paik et al. produced in-plane
single-crystal-silicon MN arrays containing microchannels
[180]. This array contained needles 2 mm in length, 100 mm wide,
and of 100 mm thickness, strong enough to tolerate a 0.248 mN of
out-of-plane bending moment and 6.28 N in-plane buckling load.
These MN arrays, when integrated with a poly(dimethylsiloxane)
(PDMS) microﬂuid chip, demonstrated efﬁcient delivery of model
solutes in both in vitro and ex vivo models. In a similar way, Roxhed
et al. developed sharp hollow silicon MN tips with side-openings
[27]. The needle tips were sealed with thin membranes to provide a
closed-package system improving the shelf-life of the integrated
MN device. To produce this device, MNs were etched on a 600 mm
thick monocrystalline silicon wafers with a two-mask process
employing an anisotropic DRIE etch through the BOSCH process
and an isotropic plasma etch (Fig. 10A). The ﬁrst process was the
etching of the needle bore from the backside of the silicon wafer,
followed by mixed isotropic and anisotropic etching from the front
side, shaping the needle geometry. The side opening of the needles
was produced in the intersection between the two-directional
etchings. Two different MN designs were produced: a 310 mm long
cross-shaped MN array and a 400 mm long circular-shaped MN
array.
Electrochemical-etching was used by Rodriguez et al. to
produce hollow silicon dioxide MN from an n-type silicon wafer
[181]. This technique was used to fabricate MNs with different
geometries and lengths (30–140 mm), with wall thickness from
70 to 110 nm and pore diameters between 2 and 5 mm. These
needles were connected to a syringe to allow a delivery of the
loaded dose with high precision. Another fully integrated
microﬂuidic drug delivery device was recently demonstrated
for treatment of hypertension [182]. The MNs in this device were
produced using a DRIE etch technique, with a series of combined
isotropic and anisotropic plasma etching steps, as described
above.
Another example of a fully integrated silicon MN system was
developed by Hafeli et al. [183]. An array of hollow out-of-plane
silicon MNs was fabricated and then integrated with a reservoir
made of PDMS. The silicon MNs were fabricated following a two-
mask MEMS process. A 40 mm wide lumen was generated through
a DRIE etch step through the back of the silicon substrate, thus
obtaining arrays with 600 needles/cm2 and shafts length of
200 mm. This array was attached to a PDMS reservoir with a
volume capacity of 12.5 ml. The surface of the reservoir was treated
with oxygen plasma and bonded with a silicon MN base.
Subsequently, the drug suspension could be loaded into the PDMS
reservoir by using an assembled MEMS syringe employing a 28 G
hypodermic needle. This device is used by placing it on the skin and
applying gentle ﬁnger pressure to the PDMS layer to deliver the
content of the reservoir to the epidermal layer.
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In terms of processing, silicon is a particularly interesting
material. It is a common microelectronics substrate, with extensive
processing experience over more than 30 years. Nevertheless, as
detailed above, these processes require long fabrication time,
include complex multi-step processes are relatively expensive and
require clean room processing [43,54].
4.1.2. Fabrication of metal and glass microneedles
In order to produce metal MN, a wide number of approaches
have been proposed, such as electroplating (e.g. palladium),
photochemical etching (e.g. titanium), and laser cutting (e.g.
stainless steel). These techniques allow, in a similar way to silicon,
routine fabrication of both solid and hollow MNs.
The simplest method to obtain metal MNs is by assembling
conventional stainless-steel hypodermic needles or stainless-steel
wires yielding hollow or solid MN respectively. Currently, the
smallest used hypodermic needles are 30 G for conventional
syringes (305 mm outer diameter) and 31 G for insulin delivery
injectors (254 mm outer diameter) [184]. These hypodermic
needles have been used to produce MNs by exposing deﬁned
lengths from a supporting material. This assembling process is
normally carried out manually. For example, Verbaan et al.
assembled commercially available 30 G hypodermic needles,
forming 4  4 arrays, supported by a poly(etheretherketone)
mould. These needles were adjusted manually to 300, 550,
700 and 900 mm heights (Figure 4A) [60,63]. Likewise, Dean
et al. and Alarcon et al. used a 1 ml syringe barrel attached to a
1 mm long stainless-steel hollow MN for vaccine delivery in rat
models in vivo [185,186]. The MN was prepared using a 34 G
commercially available hypodermic needle. In these applications,
the role of hollow MNs was similar in application to that of solid
MNs. The drug was applied in the form of a patch/solution
following MN treatment of skin. This type of design is limited
because the only viable modiﬁcations are the needle height, width
and density. An alternative to the use of hypodermic needles is the
use of stainless steel wires. Verbaan et al. prepared 4  4 MN arrays
by simply assembling stainless steel wires of 200 mm diameter and
300 mm height. In order to obtain sharp tips, the wires were cut
tangentially (Fig. 4A) [60]. In addition, a simple design of solid
metal MNs using acupuncture needles was proposed by Wu et al.
[187]. In this design, the acupuncture needles were assembled on a
silicon sheet, yielding 400 mm length MNs with a tip angle of 288.
Another approach using metal MNs was investigated by Badran
et al. using a device called the Dermaroller1 consisting of stainless
steel MNs of different needle lengths (150, 500 and 1500 mm)
protruding from a cylindrical assembly [188]. This device contains
24 circular arrays of 8 needles each (192 needles in total).
As an alternative to metal MNs, hollow glass MN can be
produced [30,77]. This type of MNs can be prepared by pulling ﬁre-
polished glass pipettes using a micropipette puller. Finally, the
resulting blunt-tip MN can be bevelled (at an angle of 35–388) and
cleaned using different solutions. Normally, these MNs are
attached to syringes and used to administer infusions. The
production of metal and glass MNs using a manual process is
not time efﬁcient and clearly not feasible for industrial purposes.
Unlike assembly of stainless steel wires, or needles, Martanto
et al. used an alternative method. An infrared laser was used to
fabricate arrays of MN shafts from 75 mm thick stainless steel
sheets [189]. In this technique, computer software was used to
draft the shape and orientation of the arrays. Subsequently, the
needles were cut using the laser (1000 Hz at an energy density of
20 J cm2), taking 4 min per array. After this, each needle was
manually bent at an angle of 908, creating an out-of-plane MN
array, followed by electropolishing using a mixture of glycerol,
phosphoric acid and water (6:3:1). Examples of this type of MN
arrays can be seen in Fig. 10B–D. This strategy is promising and
presents more advantages than the manual assembly of needles
because it allows MNs of different designs and dimensions to be
Fig. 10. (A) Process ﬂow of the fabrication of circular side-opened hollow silicon microneedles. (B) 50 out-of-plane microneedle array. Vitamin B coated (C) single and (D)
50 stainless-steel microneedle out-of-plane array.
Source: Reproduced with permission of: [22,27].
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produced. Nevertheless, it requires specialised instruments for
fabrication, which makes the process more expensive.
In addition to laser cutting and manual assembly, metal MNs
can be produced using MEMS technology. Saluja et al. prepared
titanium MNs following a photolithography/wet etching process
(see section 4.1.2.) using different titanium foil thicknesses (75,
127 and 250 mm) [190]. It was observed that the 127 mm thick
titanium foil produced MNs with a length of 454 mm and a width of
225 mm. Cormier and Dadonna [67] prepared titanium MN arrays
(321 MNs/cm2, area 2 cm2, height 200 mm, base-width 170 mm
and thickness 35 mm) by chemical etching, followed by bending
the microprojections at an angle of 908, as detailed above.
Contrasting the previously described methodologies, the
commonly used MEMS are based on the inherently planar
geometries of 2D substrates. Various techniques have been
reported to create MNs with limited height, due to restrictions
of substrate projection lithography [191]. In order to overcome this
limitation, and to create relatively ultra-high-aspect-ratio (UHAR)
metal MNs, an alternative method called ‘drawing lithography’ has
been employed. This method involves formation of a thin layer of a
thermosetting polymer (SU-8 2050) following by controlled
drawing using pillars of deﬁned patterns. This process allows
creation of 3D solid long polymeric needles that can be used as a
mould to ﬁnally create hollow metallic nickel MNs. The resulting
hollow MNs have heights of 600, 1200 and 1600 mm.
4.1.3. Fabrication of ceramic microneedles
Ceramic MNs are produced mainly by micromolding techni-
ques. These techniques will be explained in detail in the next
section. A ceramic slurry is cast inside a mould followed by a
sintering process [68,69]. This type of process allows device
production at a low cost, as this technology can be easily scaled up.
Bystrova and Luttge prepared MN arrays using this process,
obtaining a wide variety of array geometries [68]. The ﬁrst step of
the process consists of casting an alumina slurry into a PDMS
microneedle mould. Additionally, the multiple replication of the
PDMS mould offers a low cost production mould which can be
reused for ceramic micromolding. Such a micromolding process
was used by Cai et al. to prepare calcium sulphate dihydrate and
calcium phosphate dihydrate MN arrays [71]. Two types of needles,
each with different dimensions, were designed (Fig. 4D): densely
arranged pyramids 100 mm in height, 150 mm in base width and
with 160 mm between tips, and sparsely-arranged pyramids
200 mm in height, 285 mm in base width and with 820 mm
between tips. A similar micromolding process was followed by
Gittard et al. to prepare 5  5 Ormocer1 MN arrays using a two-
photon polymerisation-micromolding technique [74]. In the ﬁrst
step, two-photon polymerisation was used to fabricate a master
structure of the MN array on a silanized glass coverslip. The mould
contains MNs with base diameter values of 200 mm, lengths of 500
and 500 mm MN centre-to-MN centre spacing. The second step
consisted of replication of the MN array by means of a
micromolding process using a silicone elastomer and curing agent.
In the third step, Ormocer1 was cast into the elastomer moulds
using a vacuum process and the material was ﬁnally photo-
polymerized within the mould to produce MNs.
4.1.4. Fabrication of carbohydrate and polymeric microneedles
Polymeric MNs have been produced using a wide variety of
mould-based techniques. Some examples of these techniques are:
casting [90,94], hot embossing [192], injection moulding [31],
investment moulding [94], drawing lithography [193], laser
micromachining [194] and X-ray [88] methods. Fig. 11 shows
how some of these techniques work. Drawing lithography, on the
other hand, is a unique additive process to fabricate MNs. This
method produces 3D polymeric structures extended directly from
Fig. 11. Schemes of injection moulding, hot embossing and drawing lithography processes.
Source: Reproduced with permission of: [193].
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2D viscous polymeric materials. The polymer is cooled down until
it becomes a viscous glassy liquid. After contact of the drawing
pillars on a coated glassy liquid surface by plate moving, 3D
structures are selectively elongated from the 2D glassy liquid-plate
as a result of the longitudinal upward movement of the drawing
pillars. Then, the polymer is cured and ﬁnally isolated (Fig. 11).
During recent years, an extensive number of publications have
addressed the fabrication of polymeric MNs. Generally this type of
MNs, unlike silicon or metal, depends on the dissolution,
degradation or swelling of MNs after skin insertion by contact
with the interstitial ﬂuid in order to deliver a drug or vaccine
payload. The following sections will describe the techniques used
in the fabrication of a wide variety of MNs.
4.1.4.1. Micromolding-based fabrication of polymeric and carbohy-
drate microneedles. Micromolding involves the replication of a
master structure using moulds. To date, the majority of moulds for
MN production are made from PDMS. The main reasons for the
selection of this material are its ﬂexibility and accurate reproduc-
ibility of master structures [7]. In order to prepare moulds, master
structures can be produced using different materials (e.g. silicon or
metal) and the used as positive master templates. A wide number
of polymers have been micromolded to prepare MNs. However,
carbohydrates were initially the main candidates considered as
potential MN materials [85]. Carbohydrates change to yellow-
brown coloured substances, known as caramels, when heated at
temperatures around their melting points. This caramelization
process involves the removal of water, followed by isomerisation
and polymerisation steps, yielding a hard and brittle material.
Miyano et al. reported, for the ﬁrst time, the use of natural sugars in
the fabrication of MN arrays [85]. In this work, powdered maltose
was heated to 140 8C for 1 h and then powdered drug was added
and mixed uniformly over one minute and, ﬁnally, stored in a dry
environment at room temperature. In order to form the MN arrays,
a small quantity of this maltose-candy containing drug was then
placed onto a casting MN mould at 95 8C and cast into 500 mm high
MN arrays. The resulting MN arrays contained ascorbate-2-
glicoside, sodium salicylate and calcein. These sugar MNs should
be stored at controlled humidity, as they dissolved within a few
hours at a humidity of more than 50%. Nevertheless, they retained
their shapes for at least three months at 40% humidity. Moreover,
in another work, Miyano et al. [195] developed hydrolytic MNs
using maltose and PEG (Mw = 600 Da), obtaining MNs with lengths
ranging from 500 to 2000 mm. Another example of micromolded
maltose MNs was reported by Kolli et al. [86]. In this study, the
drug nicardipine hydrochloride was not incorporated into the MN
array itself. Instead, it was included in a liquid reservoir patch that
was applied to the skin on top of the inserted MN array. It was
shown that this type of MN array enhanced the ﬂux of nicardipine
hydrochloride in vitro across full-thickness rat skin.
Diverse authors have studied the fabrication and use of MNs
from carbohydrate materials using silicon or metal master
templates [85,86,100,195,196]. However, Donnelly et al. reported
a series of difﬁculties and limitations in the use of carbohydrate
materials for MN preparation following a micromolding process
[81]. As described previously, high processing temperatures are
required to produce hot-melts, which are extremely viscous and
resistant to ﬂow. These high temperatures (160 8C for galactose)
can cause loss of the loaded active pharmaceutical ingredient (API).
Besides, the materials produced after cooling are extremely
hygroscopic, causing problems with storage and handling.
Therefore, the authors suggested that carbohydrate-based MN
arrays are not the solution to the limitations associated with silicon
and metal MNs.
Apart from sugars, diverse materials have been also used to
prepare MNs using micromolding processes, with macromolecules
the main alternatives. For example, Lee et al. fabricated pyramidal
MN arrays made from carboxymethyl cellulose, amylopectin and
bovine serum albumin (BSA) using casting techniques. These MNs
were able to insert into cadaver skin and then dissolved within
minutes [84]. Additionally, in the same research group, Chu et al.
reported the use of a mixture of polymers: PVA and PVP, for the
production of MN arrays following a micromolding process [96]. A
10  10 array with 300 mm  300 mm  600 mm (width, length
and height) based on a pyramidal MN master template was
produced using photolithography (see Section 4.1.2) and then used
to create PDMS micromolds. Using these moulds, three different
MN designs were produced, namely solid, bubble and pedestal
MNs. Here, it was shown that incorporating a bubble into the base
enhanced the drug encapsulation in the MN tip, whereas
incorporating a pedestal at the base of the MN improved skin
insertion. The main objective of this work was to load the drug only
in the MNs tips and, therefore, increase MN loading, with minimal
wastage. This approach is particularly interesting and effective for
potent drugs. Additionally, the same research group used a
combination of micromolding and photo-polymerisation techni-
ques for production of PVP microneedles [95]. For this purpose,
vinyl pyrrolidone (liquid monomer) and azobisisobutyronitile
(free-radical initiator) were applied to PDMS moulds (arrays of
15  15, 750 mm height, and 250 mm base diameter). In order to
induce the polymerisation reaction, the moulds were placed under
a UV lamp for 30 min at ambient temperatures. The resulting PVP
MNs were strong enough to pierce the skin and dissolved in less
than one minute. Alternatively, methacrylic acid (MAA) has also
been copolymerized, producing MNs of greater fracture force and
slower dissolution rates when tested in porcine skin in vitro. In
other studies, the same research group used three types of
biodegradable polymers, PLA, PGA and PLGA, in combination with
a micromolding process for the production of MNs with different
geometries [24,92,197]. Three different types of master structures,
namely bevelled-tip, chisel-tip and tapered-cone MNs were used
to form PDMS micromolds [24]. The micromolds were then used to
fabricate biocompatible and biodegradable polymeric MNs. All
three MN designs presented strong enough needles to easily
penetrate human cadaver epidermis, increasing calcein and BSA
permeability by almost 2- or 3-orders of magnitude. Additionally,
using similar micromolding techniques and the same biodegrad-
able polymers, Park et al. produced sharply tapered MN arrays,
with enhanced insertion properties [197]. The PDMS micromolds
used in production of these MN arrays were demonstrated to be
reusable for producing polymer MNs at least 100 times. This
ﬁnding clearly illustrates the advantage of micromolding techni-
ques and their potential cost-effectiveness when compared to
expensive and complex MEMS processes.
Poly(carbonate) has been used quite often in MN production.
Based on the micromolding method, Han et al. used a casting
technique to design a prototype MN array [93]. This prototype was
produced in a series of steps. During the ﬁrst step, in-plane MNs
were fabricated using inclined UV lithography and electroforming.
Subsequently, these in-plane MNs were then aligned parallel to
each other to form an out-of-plane MN array. Using these MN
arrays, a negative mould of PDMS was fabricated. Finally,
biocompatible poly(carbonate) out-of-plane MNs were produced
using a hot-embossing machine. The same research group
proposed MN with shaft tips shaped so as to allow a reduction
of the skin insertion forces and an increase in fracture forces and
drug loadings [192]. PLA was the selected polymer for the
production of these arrays, obtaining MN with height, base width
and thickness of 880  20, 710  15 and 145  15 mm, respectively.
Moulds containing PLA pellets were heated to 190 8C and exposed to a
pressure of 20 kg/cm2 for 10 min, followed by cooling to room
temperature. Finally, the replica MN arrays were then demolded. In
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this case, the authors coated the array with an API formulation. This
process presents a signiﬁcant advantage over sugar MNs: the APIs are
not exposed to high temperatures.
Hollow polymeric MNs have been produced using micromold-
ing techniques. For this purpose, an alternative technique called
investment moulding (a combination of investment, casting and
injection moulding) was reported [94]. Cyclic oleﬁn copolymer was
used to produce hollow in-plane MNs 280 mm in height, 130 mm in
base width and of 35 mm bore diameter.
Using similar microinjection moulding techniques, Sammoura
et al. fabricated in-plane, open-channel MN devices made of a
cyclic oleﬁn and ethylene co-polymer [31]. The main components
of this design were the shank portion (4.7 mm), with an open-
channel (cross-sectional area of 0.1 mm  0.1 mm) and the base
portion, consisting of a reservoir. This MN device was applied into
beef liver, drawing approximately 0.04 ml of liquid immediately
from tissues.
X-ray radiation can also be used in lithography. In fact, a
technique known as deep X-ray lithography (DXRL), can create
high-aspect ratio hollow microstructures with sharp tips
[7]. Therefore, this technique can be used to create moulds. Using
a DXRL process, Moon et al. prepared high-aspect ratio and sharp
tip PMMA MN arrays [88]. These arrays presented needles ranging
from 750 to 1000 mm in height, with base diameter from 270 to
400 mm and bore diameter between 70 and 100 mm. These PMMA
MN arrays could be used to take blood samples from the skin on the
back of the hand. However, this method did not present any
replication technique for the MN arrays. The limitation in the
replication technique was solved by Perennes et al. In this work,
they manufactured sharp bevelled-tip PMMA hollow MNs by the
DXRL process and employed a replication technique for PMMA
hollow MN arrays using soft PVA polymeric micromolds [90]. Saw-
toothed hollow PMMA MN arrays were produced after a two-step
DXRL application on 2.7 mm thick PMMA sheets. Subsequently,
they were electroplated with a metal layer to ensure the rigidity of
the device. These MN were then used as master templates to
produce the PVA moulds. These moulds were cast with liquid
PMMA and left for 3–4 h at room temperature for polymerisation.
The PVA mould was then dissolved by immersing the system in
water at 40 8C for 2 h, leaving behind the PMMA MN arrays. PVA
was selected as the raw material to produce the moulds because
PDMS did not create efﬁcient moulds, due to a lack of stiffness of
the polymerised PDMS. A similar technique was used by Matteucci
et al. to create reusable PVA masters for PMMA MN production
[198].
The main ways to produce micromolds for MN production are
lithography, etching or the replication of a master structure.
However, there is another alternative for this purpose: laser-based
micromolding techniques [98]. Lasers have been used for material
processing extensively during the last 30 years. Due to its
monochromatic and coherent nature, a laser beam can focus its
entire power onto a spot of reduced diameter [175]. Certain lasers
have enough power to selectively ablate the material by
interacting with the chemical bonds within the material. They
have been used for different purposes, such as heat treatment,
welding, ablation, deposition, etching, lithography, photopolymer-
ization, microelectroforming and focused-beam milling of plastics,
glasses, ceramics and metals [176]. Therefore, this technology is
ideal for microstructuring of medical devices. Donnelly et al. used,
for the ﬁrst time, laser processing to produce micromolds for MN
array production [98]. By using a pulsed excimer laser beam
controlled by a computer, a deﬁned pattern can be ablated in
silicone sheets. The novel laser-based fabrication method de-
scribed can produce holes of the required dimensions
(11  11 arrays with a base diameter of 300 mm, height of
600 mm and spacing of 300 mm) in around 5 minutes (Fig. 12).
These moulds were reusable more than 50 times in micromolding
of poly(methyl vinyl ether-co-maleic acid)-based soluble poly-
meric MNs. Therefore, this method is ideal for fast and cheap
mould production. This method have been extensively used by the
same research group for production of different types of MN arrays
that are able to bypass the stratum corneum delivering a range of
different APIs [8,25,37,40].
Micromolding techniques have also been applied to production
of hydrogel-forming MN arrays. Donnelly et al. prepared such
devices using poly (methyl vinyl ether-co-maleic acid) crosslinked
by esteriﬁcation by PEG (Fig. 12D) [8]. A formulation containing
both polymers was cast into silicone moulds and then dried at
ambient temperature. To allow the crosslinking reaction between
the polymers, the moulds were placed inside a convection oven at
80 8C during 24 h. Recently, crosslinking times for this process
have been reduced to around 45 min by using microwave radiation
[199]. Additionally, different types of crosslinking processes could
be performed, such as freeze–thaw. Demir et al. cast a formulation
(gelatin and PVA) into moulds and the system were then frozen at
20 8C for 12 h, followed by thawing at 25 8C for 12 h [102].
Fig. 12. (A) SEM of the cross-section of a silicone micromold after laser engineering, revealing cone-shaped holes. (B) Digital microscope image of laser-engineered silicone
micromold (11  11) on 1.0 mm thick silicone sheet. (C) Digital microscope image of a single hole. (D) Diagrammatic representation of the steps involved in preparation of
laser-engineered MN arrays.
Source: Reproduced with permission of: [98].
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4.2. Microneedle design
The main purpose of MNs is to penetrate into the skin or any
other biological tissue without breaking or bending. An optimal
MN design should present a low insertion force and high fracture
force. In order to achieve this feature, different factors can be
optimised, such as material, fabrication method or design. The
inherent elasticity of the skin is, obviously, still a major challenge
to the reproducibility of MN penetration. Some studies showed
that, depending on the MN height, the skin could fold around the
MNs, leading to partial or incomplete piercing of the stratum
corneum [63]. Nevertheless, some MN arrays that showed good
strength failed to enhance transdermal drug delivery as they were
not able to properly pierce the skin. The main factors affecting
fracture forces and skin insertion are: type of material, needle
height, tip-radius, base diameter, needle geometry, needle
thickness, and needle density [200]. Consequently, understanding
the interaction between MNs and skin will allow design of optimal
MN arrays for clinical applications.
Understanding the mechanical properties of the skin, especially
that of the stratum corneum and viable epidermis is mandatory in
development of MN technologies. Mechanical properties of skin
were evaluated by Kendall et al. by penetrating intact stratum
corneum and viable epidermis with micro- and nanoprojections
[201]. The storage modulus, Young’s modulus and the break
strength of murine skin were investigated. It was pointed out that
the values of these mechanical properties decreased with depth
through the stratum corneum. Additionally, the authors showed
that there are some factors (i.e. thickness variation at different
body sites, and variation due to age, sex, race and body mass index)
that need consideration in order to ensure consistent application of
MN arrays. The age factor has been reinforced in recent work by
Kelchen et al. [202].
A clinical study evaluated the efﬁciency of intradermal (ID)
injection using 1.5 mm long 30 G MNs on 342 adult subjects. This
study evaluated the efﬁciency of intradermal injection as a
function of age, sex (205 women and 137 men), ethnic origin
(101 Caucasian, 118 Asian, and 123 Black Africans), body mass
index and skin thickness [203]. It was observed that, irrespective of
the age, race, body mass index or gender, the 1.5 mm long MNs,
when inserted perpendicularly, could be efﬁciently used for ID
vaccine delivery. Moreover, it was demonstrated that skin
thickness varied less between people of different body mass
index, age, sex and race than it did between different body sites on
people with similar demographic characteristics. Although these
variations in skin thickness directly inﬂuence MN-based drug
delivery, the other main factor to consider is MN geometry.
Notably, however, this study was focused on the use of an injection
system with needles longer than 1 mm. This is not the common
scenario for the majority of MN devices, which are typically
comprised of much shorter needles.
To the best of our knowledge, the ﬁrst study to demonstrate the
effect of MN geometry was reported by Davis et al. [200]. The skin
insertion forces varied in a linear way with interfacial area of the
needle tips. Additionally, the fracture force increased with MN wall
thickness, wall angle and tip radius. Finally, the safety margins
between fracture force and insertion force were high. In another
study, Davidson et al. studied the most effective MN geometry
for effective skin permeation [204]. The inﬂuence of a range of
parameters, such as MN thickness, MN diameter, coating depth of
drug on MN, penetration depth, spacing between MNs and array
pattern were all evaluated. MN designs evaluated in this study can
be seen in Fig. 13. The main parameters that signiﬁcantly affect
skin penetration were found to be: needle height and centre-to-
centre spacing of MNs. The study concluded that wider, longer
and more densely packed MNs lead to greater effective skin
permeability. In addition to this work, different studies used
theoretical models to evaluate numerous factors in MN perfor-
mance. For example, a theoretical model was proposed to evaluate
the inﬂuence of injection velocity, blood perfusion rate and tissue
porosity on MN-based transdermal drug delivery [205]. Teo et al.
showed that sharpness and type of material should be considered
for the design of MNs [206]. Different MN geometries were studied
and tested. Some examples are: straight-walled solid MNs,
straight-walled hollow MNs, and solid MNs with sharp tips. The
main ﬁnding was that, regardless of the sharpness of the tips, the
insertion of needles by hand was not very consistent and presented
some difﬁculties. In another study, the optimum MN length was
proposed to be between 50 and 200 mm [207]. In addition, Stoeber
and Liepmann pointed out that the length of the MN must be
longer than 100 mm [208]. Opposite to these ﬁndings, Pastorin
et al. reported that MN arrays with lengths less than 50 mm were
sufﬁcient for successful ID vaccine delivery [209]. Needle length is
crucial for drug diffusion from the MN tips to the dermal
microcirculation. Therefore, increase in MN length will reduce
the length of the diffusion path, increasing uptake of the drug by
the dermal microcirculation. Furthermore, needle length should
not be too short to be ineffective or too long to contact the nerve
endings in the deeper layers of dermis, causing pain. There are a
wide variety of factors affecting MN insertion and geometric and
design factors will be strongly affected by the type of material.
However, all of these ﬁndings obviously cannot be extrapolated
directly to individual types of MN arrays.
Two studies by Al-Qallaf et al. investigated the inﬂuences of a
variety of variables related to MNs and their impact on drug
transport through the skin using mathematical models
[210,211]. Some factors considered in this study were: MN length,
duration of application, size of the patch and application to
different anatomical regions. The main objective of this work was
to determine the inﬂuence of these factors on the blood drug
concentration. The main ﬁndings of these studies points out that
the blood concentration of the drug molecule can be increased by
increasing the MN length or the patch surface area. Optimised
designs for both solid and hollow MNs were proposed. In these
designs, higher skin permeability was observed by decreasing the
aspect ratio of needle height over needle radius and the number
of MNs was increased. Notably, however, these ﬁndings were
obtained using a theoretical model which would need to be
experimentally validated. Overall, the optimum MN design should
be long enough for transdermal drug delivery applications without
causing pain; should present low insertion forces and high break
force; its density should be tailored to deliver the desired amount
of the active compound; it should be designed to be applied on a
speciﬁc anatomical location within the body; it should have a
certain degree of ﬂexibility to overcome skin contours; it should
avoid skin deformation to allow complete MN penetration.
Another critical factor that should be taken into account in MN
design is the application method. There are two main methods of
application, manual and applicator based. The range of forces that
both methods can apply should be taken into consideration.
4.3. Microneedle mechanical characterisation
A crucial step in the development of successful MN devices is
mechanical characterisation. MNs normally experience a wide
range of stresses, including those experienced during insertion or
removal. Therefore, it is mandatory for such devices to possess
inherent strength to avoid failures [47]. There are a wide number of
failure modes that these stresses can cause, including MN bending,
buckling and base-plate fracturing [52]. Therefore, mechanical
characterisation should be performed in order to ascertain that
the designed MN are safe prior to use. As there is no single test
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simulating MN insertion in vivo, characterisation consists of a
range of tests. One of the ﬁrst MN mechanical tests described was
developed by Zahn et al. [52]. This test consisted of a single, hollow,
silicon MN and a force gauge that gradually increased the vertical
force being exerted at the MN tip (0–20 g range) until it fractures.
Since then, numerous methods and tests have been developed for
MN mechanical characterisation.
4.3.1. Axial force mechanical tests
Axial force mechanical tests involve applying a force to the MNs
perpendicular to the base-plate [98]. This type of test normally
needs the use of a mechanical test station, which records both
displacement and force while the MNs are pushed against a hard
surface at a deﬁned rate [24,102] (Fig. 14A). When MN fracture
occurs, a sudden decrease can be observed in the force-displace-
ment curves generated. The maximum force exerted immediately
before this drop is normally taken as the MN failure force
[24]. Images of the MN arrays can be taken before and after fracture
to provide insights into the mode of failure [212]. Some axial force
tests reported in the literature should be viewed with caution, as
they only use a single MN [52,213]. The failure force of a MN array
obviously cannot always be assumed to correlate with that of a
single MN. Additionally, it is important to clarify that this test does
not accurately simulate the forces experienced by MNs during
insertion into the skin. In this test, MNs are pressed against a hard
surface, leading to a concentration of the forces at the MN tip.
During insertion of MN into skin, the forces are distributed over a
greater MN area, as the ﬂexible skin wraps around the MN
projections [212].
4.3.2. Transverse force and shear strength mechanical tests
Skin surface irregularities and its natural elasticity often lead to
incomplete insertion of MN arrays, with transverse bending of the
needles also frequently observed. Therefore, a transverse fracture
force test is necessary to probe the behaviour of MNs during
application [24,102]. Using a mechanical test station, a transverse
force (applied normal to the MN y-axis) is applied at a deﬁned
point on the MN shaft until the MN fractures (Fig. 14). Again, a
sudden drop in the force-displacement curves indicates MN failure
[98,102]. When this test is applied to a row of MNs rather than to a
single MN, the force should be divided by the number of MN in the
row to calculate the transverse fracture force per individual MN
[98]. The main limitation of this test as reported in the literature is
the requirement to align the metal probe with a deﬁned length
manually [98]. This can lead to experimental inaccuracies, even if
the test is performed with the aid of a microscope camera [102].
4.3.3. Base-plate strength and ﬂexibility tests
The tests described above are focused on mechanical testing of
the needles themselves, but assessment of the MN base-plate
strength is also important. Clearly, fracture of the base-plate
during patient application is not acceptable. Therefore, base-plates
need to be ﬂexible enough to conform to the topography of the skin
without fracturing [98]. For this purpose, a three points bending
Fig. 13. Different MN designs.
Source: Reproduced with permission of: [204].
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test has been used [98]. Donnelly et al. used a Texture Analyzer to
apply forces using a metal probe to base-plates placed between
two aluminium blocks (Fig. 14C). A maximum peak observed in the
force-distance curve represented the force required to break the
base plate. Additionally, the baseplate bending upon fracture was
calculated in order to evaluate the ﬂexibility of the base-plate (Fig.
14C).
4.3.4. Importance of microneedle mechanical test results
The importance of the experimental testing of MN failure forces
can only be properly assessed when compared with the equivalent
insertion forces [24]. For this purpose, the parameter ‘margin of
safety’, the ratio of MN fracture force: insertion force, is a valuable
index [24,213,214]. Naturally, human or animal skin tissue is
required to measure the insertion forces. In the majority of studies
researchers evaluate the ability of the MNs to pierce the skin using
techniques such as microscopy or histological analysis. However,
these experiments do not give information about the insertion
forces required to pierce the skin. However, there are some
published studies where the MN insertion forces were measured.
For example, Davis et al. measured the insertion forces of metal MN
(radii varying between 30 and 80 mm) in human volunteers using
a force-displacement measurement device [213]. The obtained
insertion forces (0.08 and 3.04 N per needle) suggested that this
process allows manual insertion. Using the same method, Khanna
et al. measured the insertion forces of 4  4 hollow silicon MN
arrays using cadaver skin [215]. In this case, the obtained insertion
forces ranged between 4.75 and 0.1 N determined mainly by the tip
sharpness. Loeters et al. described a method to measure insertion
forces using a MN integrated with electrodes device [216]. This
method was used to evaluate the skin insertion forces of a
9  9 MN array, showing that 2.6 N were required for this purpose.
Using electrical impedance measurements in the skin, Roxhed
et al. evaluated the insertion force of a novel design of ultrasharp
MNs in human skin [217]. The results showed that the required
forces were lower than 10 mN. Another critical parameter for MN
design as pointed out above is the fracture force. For all types of
MNs, the fracture forces should be signiﬁcantly greater than the
force required for insertion into the patient’s skin. As described
above, MN array designs can be optimised to increase their ‘margin
of safety’ value [24,214].
In order to deﬁne the margin of safety, the nature of the
insertion process should be studied. MN can be inserted manually
or by using an applicator. A wide variety of applicators can be
found in the literature [7]. When using an applicator, the insertion
conditions are controlled. When using manual insertion, the
process obviously presents more variability. Consequently, the
range of forces that patients can apply by hand should be taken into
consideration to deﬁne the margin of safety. In a recent study,
Larran˜eta et al. concluded that the range of manual forces applied
by 20 volunteers, following instructions for MN insertion, ranged
between 10 and 50 N, with an average value of 20 N.
MN mechanical characterisation tests are commonly used to
ascertain the mechanical strength of MN arrays. However, due to the
range of MN geometrical dimensions, the diversity of tests employed
and the range of measuring equipment utilised, direct comparison
between different MN designs cannot be made. To overcome this
important limitation, MN technology would beneﬁt from the
development and consolidation of standardised mechanical tests.
4.4. Microneedle Insertion measurements
There are different techniques to demonstrate successful MN
insertion. Normally, these require biological tissue and/or complex
Fig. 14. (A) Digital photograph of MN pressed against the metal mill during axial fracture force. (B) MN shafts were transversely pressed against the metal mill for
measurement of the transverse fracture force. (C) Illustration of the Texture Analyzer set-up for base-plate strength and ﬂexibility test.
Source: Reproduced with permission of: [102].
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techniques. The most used is the staining of MN-treated skin using
coloured dyes, such as methylene blue or trypan blue
[80,194,218]. These dyes stain only cells of the viable epidermis
and not the stratum corneum identifying MN-created microchan-
nels. Alternatives to the staining are transepidermal water loss
[194,219] or electrical impedance measurements [213,217] after
MN insertion. Both techniques can ascertain if the barrier function
of the stratum corneum has been reduce. However, such techniques
cannot provide quantitative information on MN insertion depth. In
order to obtain insertion depth data, histological cryosectioning
with adjunct staining [216,217], confocal microscopic imaging
[212] and optical coherence tomography [105] can be used. The
latter is the best option, as it does not require skin excision or
mechanical manipulation of samples and allows measurements in
real time [105]. However, all these techniques require the use of
biological tissue. Recently, Larran˜eta et al. proposed an artiﬁcial
membrane as a skin model for MN insertion studies [38].
The relevance and interpretation of MN insertion studies is
limited by a number of factors, such as the materials and geometry
of MN arrays, use of varying experimental protocols and different
skin models. These limitations could lead to divergence of results
using different methods of analysing MN penetration, even though
the MNs and skin samples used remain the same. Therefore,
standardised MN test protocols should be developed.
5. Microneedles: applications and translation to clinic
5.1. Microneedle applications
5.1.1. Drug delivery
The wide variety of MN types described previously reﬂects the
extensive nature of research into MN technology. During the last
20 years, a wide variety of studies have demonstrated the
substantial drug delivery enhancing effects of MNs.
As detailed above, Henry et al. published the ﬁrst research work
using MN for transdermal drug delivery [15]. This work described
the use of solid silicon MNs for the delivery of calcein (model drug)
using the ‘poke and patch’ approach (see Section 2.2). Since then,
this approach have been used extensively employed, using mainly
silicon and metal MNs. McAllister et al. reported the use of metal
MNs for the delivery of different molecules, including macro-
molecules, such as BSA and insulin [80]. Photosensitisers [5-
aminolevulinic acid, 5-aminolevulinic acid methyl ester and meso-
tetra(N-methyl-4-pyridyl)porphine tetratosylate] were also deliv-
ered after a pre-treatment with solid polymeric [220] and silicon
MN arrays [17]. Additionally, Stahl et al. showed the transdermal
permeation enhancement of non-steroidal anti-inﬂammatory
drugs (diclofenac, ibuprofen, ketoprofen, paracetamol) using a
pre-treatment with MN roller devices [221]. In some studies, this
strategy was used in combination with other enhancement
strategies, such as iontophoresis or sonophoresis, showing a
synergistic effect in the enhancement of transdermal delivery of
macromolecular compounds [187,222].
Coated MNs have been used in transdermal permeation
enhancement of a wide variety of compounds, such as ﬂuorescein
sodium [223], salmon calcitonin [224], desmopressin [67] and
parathyroid hormone [225]. In addition to drugs, coated MNs have
been also used for DNA delivery. For this purpose, DNA solutions
can be dip coated onto MNs [218]. This system may present an
attractive and effective treatment option for genetic skin diseases
and cutaneous cancers. Additionally, metal MNs have been coated
with RNA, leading to in vitro and in vivo silencing of gene
expression [226].
Dissolving MNs have been extensively used to enhance
transdermal and ID delivery of numerous drugs and biopharma-
ceutical molecules. Small molecules delivered using dissolving MN
include caffeine, lidocaine, metronidazole [227], ibuprofen sodium
[104], sulforhodamine B [84] and 5-aminolevulinic acid
[81]. Macromolecules delivered using dissolving MNs include
insulin [228,229], low molecular weight heparin [230], ovalbumin
[231,232], leuprolide acetate [233], erythropoietin [196] and
human growth hormone [234].
To date, insulin has been the most extensively delivered
molecule using hollow MNs [29,30,235]. However, hollow MNs
have also been used for ID delivery of smaller molecules, such as
sulforhodamine [77].
Hydrogel-forming MN arrays have been used to deliver
clinically relevant doses of a low potency, high dose drug substance
and also for rapid delivery of proteins [25]. Studies carried out with
hydrogel-forming MN arrays the show their ability to enhance
percutaneous delivery of a wide variety of molecules, such as small
hydrophilic drugs (i.e. theophylline, caffeine, methylene blue and
metronidazole) and high molecular weight compounds (i.e. insulin
and BSA) [8].
5.1.2. Vaccine delivery
The viable skin is viewed as an ideal target for vaccine delivery.
It contains a large network of immunologically active cells and
antigen-presenting cells (APC) responsible for initiating adaptive
immune responses (Fig. 15) [236,237]. Additionally, skin vaccina-
tion presents a dose-sparing effect when compared to convention-
al intramuscular (IM) vaccination. This effect is due to the higher
numbers of APCs present in the skin, leading to induction of
stronger immune response with lower antigen levels [238]. As a
result, MN vaccination has become an area of intense activity in
recent years.
The main type of MN used for vaccination purposes is dissolving
MN. Cell-culture-derived inﬂuenza vaccine has been loaded and
delivered using trehalose and carboxymethyl cellulose dissolving
MNs with considerable effect [239]. MN vaccination against
inﬂuenza was further exempliﬁed by using diverse approaches,
such as delivering trivalent inﬂuenza vaccine in combination with
ovalbumin using carboxymethyl cellulose MNs [240] or N-
vinylpyrrolidone MN containing inactivated inﬂuenza vaccine
[241]. In addition to inﬂuenza vaccination, Zaric et al. combined
ovalbumin (as model protein)-loaded PLGA nanoparticles in
combination with dissolving poly(methylvinylether-co-maleic
acid) MNs to target dendritic cells, inducing considerable Th1
CD4+ and potent cytotoxic CD8+ T cell responses [242]. Hyaluronic
acid MNs (Microhyala1) were used by Matsuo et al. to investigate
vaccine efﬁcacy against tetanus, diphtheria, inﬂuenza and malaria,
obtaining in all cases immunisation results comparable with the
parenteral route [243]. Additionally, the same research group used
the hyaluronic acid MN system to try to develop a vaccine for
Alzheimer’s disease, delivering an amyloid-beta 42-amino acid
peptide as an antigenic stimulant [244]. Even though results did
not show improved brain function in those patients treated, it
demonstrated that efﬁcient anti amyloid-beta immune responses
can be attained after MN application.
Coated MN arrays have been used successfully for vaccination
purposes. For this purpose, different types of solid MN arrays can
be coated with antigen-containing formulations. Stainless steel
MNs coated with a vaccine against the Edmonston-Zagreb virus
was used to successfully raise neutralising antibody titres
equivalent to subcutaneous injection [245]. Inﬂuenza vaccination
was also explored using coated MNs. Kommareddy et al. developed
an inﬂuenza antigen coated MN system that elicits comparable
antibody titres to IM injection [246]. Additionally, Zhu et al. and
Wang et al. developed inﬂuenza vaccine-coated MNs, showing
good immunisation results, in some cases superior to IM delivery
[247,248]. Following a different vaccination strategy, Vrdoljak
et al. delivered live virus vaccines, achieving equivalent immune
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responses to that of a conventional vaccine delivery approach
(needle and syringe) using equivalent doses [249]. Vaccination
with DNA and RNA in combination with MNs is beginning to
show potential. DeMuth et al. developed a lipid nano-capsule
loaded with DNA vaccine for a model of human immunodeﬁ-
ciency virus, achieving similar results to that of gene gun
technology [250]. Additionally, Kim et al. in a more resent study,
proposed an Alzheimer’s disease vaccine be delivered using
coated MN arrays [251]. The study showed that a robust
humoral response, comparable with subcutaneous injection,
could be achieved.
Finally, the last type of MN used for vaccine delivery is
hollow MN. This type of vaccination is similar to conventional
parenteral vaccine delivery, as one or more hollow needles are
used to deliver the vaccine liquid formulation. In this case, the
needles are between 1 and 1.5 mm in length and the injected
volumes are less than 200 ml [252]. These systems have been
designed to improve the Mantoux technique, consisting of
insertion of a dermal needle into a patient’s skin using a shallow
angle. This technique is difﬁcult to perform, leading to
inconsistent responses [253]. Anthrax vaccination using rabbit
models showed a dose reduction up to 50-fold when adminis-
tered using hollow MN instead of IM injection [254]. Addition-
ally, the rabbit survival proﬁles were equivalent to those
injected using the IM route. Dose-sparing studies conducted
with a rabies vaccine in healthy humans demonstrated that MN
delivery showed an adequate immune efﬁcacy in comparison
with IM injection [255]. Another therapeutic approach was the
inclusion of multiple vaccine-components combined into a
single product. Moreﬁeld et al. successfully used hollow MNs to
deliver a combination vaccine against anthrax, botulism, plague
and staphylococcal toxic shock in rhesus macaque monkeys
[256].
5.1.3. Patient monitoring and diagnosis
Blood extraction for patient monitoring or diagnostic purposes
presents some drawbacks, including needle-phobia, need for
trained healthcare staff and risk of infection associated with
conventional needles, amongst others. MN have the potential to
overcome these limitations. MN can be designed in a similar way to
hypodermic needles, allowing interstitial ﬂuid extraction from the
skin [257]. Interstitial ﬂuid represents a good medium for analyte
monitoring, as the concentration of molecules in this ﬂuid can
often be correlated accurately with their blood concentrations.
Therefore, MNs offer the possibility of a pain and blood free
monitoring/diagnosis system (Fig. 16A).
The ﬁrst MN extraction systems were based on capillary action
of interstitial ﬂuid. Novel strategies involve the use of more
complex extraction mechanism, such as vacuum or osmotic
pressure [257]. Glucose monitoring have been investigated using
hollow glass MNs. The designed MN device was used to extract
interstitial ﬂuid from hairless rats and human volunteers using a
vacuum over 2 and 10 min. Results from this study showed that the
concentrations of glucose in interstitial ﬂuid can be correlated with
blood glucose [258]. An alternative to MN interstitial ﬂuid
extraction is the use of longer MN (upper-end of the micron
scale) for capillary blood extraction (Fig. 16A). This method offers a
less invasive procedure than conventional hypodermic needles.
Hollow metallic MNs (1800 mm height, 60 mm inner diameter,
120 mm tip diameter and 150 bevel) were used by Li et al. for blood
extraction. The authors claimed that this device allows blood
extraction with low risk of pain inducement. This device was used
to extract 20 ml of blood from mouse-tail vein [259]. A different
approach for interstitial ﬂuid extraction is the use of hydrogel-
forming MN arrays. Once they are inserted, they swell, taking up
skin interstitial ﬂuid, depending on the degree of polymer cross-
linking. Subsequently this swelled patch can be analysed in order
Fig. 15. A schematic view of the different cell types populating the skin. The stratum corneum is composed of dead keratinocytes and acts as a barrier. The epidermis is a dense
and poorly vascularised region that comprises mainly of keratinocytes with few melanocytes. The major immune cells in this compartment include Langerhans cells (APCs),
dendritic epidermal T-cells, and CD8 T-cells. The dermis is a highly vascularised region, rich in collagen, and elastin ﬁbres, with low cell density. It comprises of ﬁbroblasts, T-
cells (CD4 ab, and gd), innate lymphoid cells (ILCs), dermal DCs (dDCs), macrophages, mast cells, and neutrophils (non-exhaustive list).
Source: Reproduced with permission of: [236].
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to quantify different analytes and/or biomarkers (Fig. 16B)
[257,260]. The development of integrated systems, which negate
the need for off-site analysis after extraction of ﬂuid and instead
rely on the use of integrated sensors, has also been explored for
many of the devices described previously (Fig. 16).
A different approach in the use of MN for monitoring purposes
was proposed by O’Mahony et al. [261]. A MN system for
electrocardiography signal optimisation was proposed. The
stratum corneum, due to its high electrical impedance, causes
signiﬁcant interferences in the signal acquirement when using this
technique. Therefore, with a view to optimisation, alternative
approaches have been investigated, such as application of
electrolytic gels or skin abrasion. The use of electrocardiography
in combination with silicon MN arrays (25 needles with 300 mm in
height) connected to two electrodes allowed the recording of
images with comparable quality to conventional ones. This system
has other potential applications, such as electroencephalography
and electromyography.
5.1.4. Cosmetic applications
MN can be used for cosmetic applications, mainly for treatment
of skin blemishes and the delivery of active cosmetic ingredients.
Therefore, the cosmeceutical industry has shown great interest in
MN technology [262,263]. Kim et al. developed a hyaluronic acid-
based dissolving MN patch for the intradermal delivery of ascorbic
acid and retinyl retinoate [264]. These MN systems were tested
using human volunteers, displaying improved skin appearance in
terms of roughness and wrinkle appearance. In order to obtain
these results, MN were applied twice a day for 6 h at a time. Such
conditions are, obviously, not ideal for cosmetic purposes.
Recently, Kumar et al. showed an enhancement of local delivery
of eﬂornithine (used to reduce facial hirsutism) in vitro and in vivo
[265]. For this purpose, the skin was treated with MN followed by
local administration of an eﬂornithine cream. Importantly,
combination of MNs and commercially available topical products
intended for application to intact skin should be treated with
caution, since some adverse reactions, such as granulomas, have
been reported by using non-sterile topical products [266].
MN technology can be used to treat different types of scars by
dermabrasion [267–271]. MN dermabrasion consists of the use of
MN to pierce the skin multiple times to induce collagen growth.
Fabbrocini et al. treated patients with acne scars using a
Dermaroller1 treatment, reporting aesthetic improvement, with
a reduction in scar severity in all subjects [269]. Patients were
treated twice (eight weeks apart) with the needle roller (up to
2 mm in length), creating 250–300 microscopic holes/cm2. To date,
the skin recovery mechanism has not been fully elucidated, but it
has been hypothesised that the treatment with MNs increases
production of collagen and elastin. Nevertheless, this treatment is
not optimal as, due to the needle length, it induced skin bleeding.
Similar results were obtained by Majid using a dermarroller for
treatment of atrophic facial scars [272]. Additionally, Park et al.
used a disc MN therapy system for treatment of dermal scars (striae
distensae), obtaining noticeable improvement in 7 out of
16 patients [268]. However, this treatment has the same
limitations as those described previously for acne, namely skin
bleeding and painful treatment.
In addition to the use of Dermaroller1, an alternative approach
for the treatment of acne scars has been reported, the fractional
radiofrequency MN system. This system was introduced recently as
a new device for facial rejuvenation [273]. This system works by
creating radiofrequency-induced thermal zones without epidermal
Fig. 16. Microneedle-based strategies for minimally invasive patient monitoring through blood or interstitial ﬂuid extraction with on-board or off-site analysis. (A) Hollow
MN for extraction of interstitial ﬂuid or blood enabling indirect and direct quantiﬁcation of plasma levels of analytes of diagnostic or therapeutic interest. (B) Hydrogel-
forming MN for interstitial ﬂuid capture and the possibility of ‘‘connected health’’ applications.
Source: Reproduced with permission of: [257].
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injury. After damage to the reticular dermis, dermal thickening
occurs. This system was clinically evaluated by Chandrashekar et al.
[273]. The results suggested that this novel technique is efﬁcacious
for the treatment of acne scars, as it reduced the severity of the scars
in more than 80% of volunteers.
5.1.5. Other potential applications
There are increasing reports of alternative uses of MN beyond
those previously described. Recently, Yang et al. reported the use of
MN system improving skin graft adherence [274]. For this purpose,
conical shaped MNs composed of a non-swelling core and a
swellable tip were prepared using poly(styrene) and poly(acrylic
acid) polymers. This medical device showed enhanced tissue
adhesion strengths in comparison with the conventional staple
system used for this purposes. This MN system can be inserted
with minimal forces and allows the loading of therapeutic agents
in the tips for a combined tissue adhesion and drug delivery
strategy.
The use of MNs for alternative target areas other than the skin
was studied by some authors. Thakur et al. [275] investigated the
use of hollow MNs for the injection of thermoresponsive
poloxamer formulations into rabbit sclera. The formulation
contained ﬂuorescein sodium as model compound. This MN-based
system allows intra-scleral injection in a minimally invasive
fashion when compared with traditional methods. The injected
formulations forms a gel in situ, creating a drug reservoir that
allows sustained release of loaded molecules. An interesting
alternative for the use of MN arrays was proposed by Lee et al.
[276]. They demonstrated the therapeutic performance of MN
devices in treating neointimal hyperplasia that often occurs at
anastomosis sites after grafting surgery. MN were inserted into
vascular tissue layers in a rabbit balloon injury model. MN were
coated with drugs, such as paclitaxel. These studies conﬁrmed that
the use of these MN arrays leads to a signiﬁcant reduction of
neointimal hyperplasia formation after both 2 and 4 weeks
following balloon injury.
5.2. Translation to clinic
5.2.1. Microneedle safety
MN are not equivalent to conventional transdermal patches, as
they are not applied to the skin surface. As explained previously,
MN works by piercing the outermost protective skin layer. In some
cases, MN penetrate into both the viable epidermis and dermis,
normally sterile areas of the body [277]. Therefore, it is mandatory
that MN products do not contain microbial loads that can cause
skin or systemic infections. Additionally, the bioburden of these
products should be controlled and minimised to avoid immune
stimulation of the immune cell population present in the viable
epidermis and dermis [278]. Microbial penetration through MN-
created holes is minimal and signiﬁcantly lower to that elicited
using conventional hypodermic needle puncture [279]. Conse-
quently, in normal circumstances, the use of MN should not cause
infection. Wei et al. showed similar results in vivo, using MN laced
with Staphylococcus aureus [18]. Certain materials used for MN
production can show antimicrobial properties, further minimising
infection risks [40]. In order to guarantee patient safety, a possible
solution may be the production of sterile MN products. Neverthe-
less, the sterilisation methods should be considered carefully to
avoid modifying the original nature of the product and increasing
manufacturing costs. For example, aseptic manufacturing will be
expensive, terminal sterilisation using gamma irradiation, moist
heat or microwave heating could damage the MNs or their cargos.
Some of these issues were addressed by McCrudden et al. [280].
In this work, the effects of different sterilisation methods on
dissolving and swelling MN products were evaluated. Another key
aspect, as discussed previously, is the biocompatibility of the
materials selected for MN manufacture (see Section 3.2). It will be
obligatory that no local or systemic reactions to the materials used
to fabricate MNs occur. Biocompatibility and safety studies can be
performed for different materials. Nevertheless, to date little is
known about long-term effects of repeatedly penetrating the skin.
When using polymeric dissolving MN systems, an additional
safety consideration arises: polymer deposition in the skin.
Typically selected polymers for MN manufacture have been
previously classiﬁed as biocompatible and safe. However, due to
the novelty of MN systems, normally these polymers have never
been used before intradermally. This question should be
addressed, especially for dissolving MN systems designed for
regular use.
5.2.2. Microneedle application and patient acceptability
In order to increase patient and prescriber compliance, MN
patches must be viewed as an easy-to-use alternative to oral and
parenteral delivery. Additionally, the FDA draft guidance ‘Applying
Human Factors and Usability Engineering to Optimise Medical
Device Design’ highlights the importance of an easy-to-use device
that can be use successfully with minimal chance of error prior to
marketing [281].
A common way to insert MN arrays is by using applicators. A
wide variety of these devices can be found in the literature,
especially in patents [282]. However, only some of them are
commercially available. These devices often use high-impact,
velocity or rotary designs to apply MNs in a deﬁned way, ensuring
minimal inter-individual variability in skin insertion [282]. The
majority of applicator devices are based on impact application. One
of simplest approaches is to use a spring-loaded piston. Some
examples of MN applicators using this principle were developed by
Zosano Pharma (Fig. 17A) and 3M Innovative Properties Company
[282]. Mainly, these types of device are based on a piston that is
accelerated using a coilED compression spring towards the MN
array that is placed on the surface of the skin. High impact insertion
can be achieved using different approaches, such as using an elastic
band rather than springs [282], as shown in Fig. 17B. In this design,
prior to insertion of the MN device the band is strained by pulling
the MN array away from the skin to a predetermined distance.
Then, the connecting membrane detaches from the elastic band
allowing the band to snap back towards the skin, inserting the MN.
Such devices were able to successfully insert MN arrays. The
previously-described applicators are easy-to-use but, due to their
high impact mechanism, these types of devices may not be the best
options since they may be perceived as painful by patients. Simpler
applicator mechanisms can be found in the literature. These types
of applicators are designed to use thumb pressure [282]. Corium
International Ltd (Fig. 17D) and 3M (Fig. 17E) have designed
applicators following this premise. These applicators should be
placed on the surface of the skin and then pressed, allowing the MN
arrays to be inserted. By using applicators, the insertion process is
controlled. However, the application is more complex than that of
conventional transdermal patches and may be perceived as overly
complex by patients.
A different alternative to applicators is to use manual insertion.
Manual insertion allows a simple and patient-friendly way to
insert the arrays. On the other hand, insertion is not controlled as it
is when applicators are used. Nevertheless, Donnelly et al.
demonstrated that hydrogel-forming MNs can be manually self-
applied by patients in a consistent way with no applicator when
counselled by a pharmacist and having read a suitable patient
information leaﬂet [11]. In a similar study, Norman et al. showed
that the use of MN for vaccination, instead of hypodermic needle
injection, lead to an increase in ‘‘vaccination intent’’ from 44% to
65% [283]. The same study showed that MN self-application with
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minimal volunteer training was successful, allowing at least 90% of
MNs to penetrate the stratum corneum. Finally, Birchall et al. and
Donnelly et al. pointed out that patients are likely to prefer MN
with some feedback in response to correct application [11,284]. Ad-
ditionally, Birchall et al. evaluated MN acceptability by healthcare
professionals and members of the general public [284]. The main
conclusion of this study was that 100% of the public and 74% of the
healthcare professionals interviewed were positive in their
feedback about MN technology. Moreover, in a recent study
Mooney et al. evaluated the potential for use of MN in monitoring
applications for children [285]. Overall, this study showed strong
support for MN technology by the interviewed children in
comparison with the unpopularity of traditional blood sampling
methods. Nonetheless, further work in this area was recommended
to evaluate the perspectives of children that require regular
monitoring. Moreover, Norman et al. studied the delivery of insulin
to children and adolescents suffering from type 1 diabetes using
MNs [286]. The volunteers found MN insertion less painful than
subcutaneous catheter insertion. All of these factors and consider-
ations should be taken into account for the design of future MN-
based devices. Additionally, aspects such as the necessity of an
applicator or the suitability of manual insertion should be
evaluated by regulatory authorities.
5.2.3. Scale-up and manufacturing considerations
Manufacturing MN aseptically, in low bioburden environ-
ments or employing terminal sterilisation procedures are likely to
increase cost considerably. Scaling up MN production will require
considerable thought. This is especially true given the plethora of
small-scale production methods described in the literature. Very
often a number of steps are required, especially for coated MN.
Silicon MN requires clean room conditions. Overall, it is likely that
any manufacturer wishing to develop MN products will need to
make a substantial initial capital investment, given that equiva-
lent manufacturing technologies are not currently available.
Similarly, a range of new quality control tests will now also
become necessary. It is likely that the regulatory requirements set
for the ﬁrst MN products to be approved for human use will set the
standards for follow-on products. Packaging will be important in
protecting MN from moisture and microbial ingress and suitable
advice will need to be provided to avoid damage during patient
handling and insertion.
5.2.4. Regulatory considerations
To the date there are no regulatory requirements deﬁned for
MN array-based products, due mainly to the innovative nature of
this technology. This issue will have to be addressed in the coming
years when companies intending to commercialise MN patches
apply for marketing authorisation. Conventional transdermal
patch systems are only applied to the surface of the skin. However,
MN breach the stratum corneum barrier and often penetrate into
the viable epidermis and dermis. Breaching the outermost
protective layer of the skin generates a series of novel scientiﬁc/
regulatory questions. Therefore, the totally different mechanism of
action suggest that, from a regulatory perspective, MN will be
deﬁned as a new dosage form instead of a special type of the pre-
existing transdermal patch systems. Additionally, speciﬁcations
for these new products should be deﬁned. The International
Fig. 17. (A) Zosano’s Macroﬂux1 applicator device at different stages of the insertion process. (B) Elastic band applicator device prior to insertion of MN device it is stretched so
that the MN device is pulled away from the skin at predetermined level the connecting membrane detaches from elastic band, thereby allowing the band to snap back towards
the arm subsequently causing the MN insertion into the skin. (C) MicroCorTM MN device. (D) 3M patented device.
Source: Reproduced with permission of: [282].
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Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use provided guideline
to assist the establishment of global speciﬁcations for new drug
substances and drug products which have not been registered
previously in the United States, the European Union or Japan
[287]. These guidelines are known as Q6A. According to these
guidelines, speciﬁcations are deﬁned as follows: ‘‘A list of tests,
references to analytical procedures, and appropriate acceptance
criteria, which are numerical limits, ranges, or other criteria for the
tests described. It establishes the set of criteria to which a drug
substance or drug product should conform to be considered
acceptable for its intended use’’. Speciﬁcations are an important
part of the quality assurance system and are necessary to
guarantee consistent production of drug substances and drug
products of high quality [287].
In summary, the key regulatory questions that may need to be
addressed for the establishment of MN product speciﬁcations are
as follows:
1. Microbiological standards of the MN dosage form. MN dosage
forms pierce the stratum corneum, reaching the dermis in some
cases. Therefore, microbiological standards will be an impor-
tant regulatory consideration. It may be acceptable for a
product to have a low bioburden if it also has an inherent and
proven antimicrobial activity.
2. Uniformity of content. This is a common pharmacopoeial
requirement that should be applied to MN systems. However,
depending on system design, this requirement can be applied
either for the system as a whole or to individual drug-loaded
MN within an array.
3. Manufacturing aspects. The normal aspects of quality applied to
other dosage forms. Additionally, security packaging should be
applied.
4. Potential for re-use by patients or others. Many MN systems,
especially those made of silicon, metals and ceramic, can be
removed intact from the skin after use. Thus, they could be re-
used by the same patient or a different one. Due to safety
reasons, a self-disabling system, guaranteeing a single-use
only, may be required.
5. Disposal. As described above, some of the MN devices are not
dissolvable/biodegradable and can be easily reinserted. There-
fore they can be hazardous and a safe disposal procedure
should be required.
6. Deposition of MN materials in the skin. Dissolvable, polymeric
MN could deposit in the skin the materials from which
they were fabricated, leading to adverse skin effects, such as
granuloma formation or local erythema. This could be
mitigated by alternating the application site. This issue should
be addressed, as mentioned previously, especially for long-
term use MN products. This is unlikely to be a major problem
for single use application MN products, such as vaccines.
7. Ease and reliability of application by patients. Patients should be
able to use the products in the optimum way without
complications.
8. Proper insertion assuring delivery. As MN insertion produces no
pain or obvious sensation, there is no feedback for the patient.
A system that indicates correct application may be required.
9. Immunological effects due to repeated use. The repeated
insertion of MN in the skin could possibly lead to immunologi-
cal reactions. Therefore, assurances regarding immunological
safety should be provided to the regulators.
10. Long-term safety proﬁle. To the date, there are short-term safety
studies with human volunteers. However, long-term safety
of MN application should be addressed from the perspectives
of intermittent and frequent repeat applications.
5.2.5. Commercialization of MN arrays
MN present substantial advantages over conventional trans-
dermal patches, especially in terms of the delivery of biopharma-
ceuticals. Therefore, during the past decade, there has been a
signiﬁcant increase in industrial activity in this area. Currently, a
certain number of MN-based products are being developed by
different companies, including: Zosano Pharma (USA), 3M (USA),
Sanoﬁ Pasteur MSD (USA), Becton-Dickinson (BD) Technologies
(USA), Valeritas (USA), Nanopass Technologies (Israel), Micro-
needle Therapy System (USA) [9], Rodan+Fields (USA), Vaxxas
(Australia), Corium (USA) and, more recently, Lohmann Therapie-
Systeme AG (Germany/USA), the world’s largest transdermal patch
manufacturer [288]. It is notable that no MN array-based drug
delivery product is yet marketed. Micronjet1 (Nanopass) and
Soluvia1 (BD) are available, yet they are not truly MN arrays, rather
very short hollow needles that allow successful ID injection from a
conventional syringe barrel.
3M developed the Microstructured Transdermal System1
(Fig. 18A), a device formed by coated MN arrays that allows
improved delivery of some drugs and vaccines in a quicker way.
This system showed a rapid delivery of lidocaine, with adminis-
tration sustainable for up to 90 min [289].
A different type of device was developed by BD Technologies,
the Microinfusor (Fig. 18B). This is an automated hands-free
system designed for delivery of a wide range of drugs to the
subcutaneous tissue over a period of time, ranging from a few
seconds to several minutes. This hollow MN system has a capacity
of 0.2–15 ml and allows the delivery of highly viscous biotech
drugs. The delivery of inﬂuenza vaccine with the same effective-
ness of a conventional intramuscular injection was shown in
preclinical studies [186].
Alza developed Macroﬂux1. This system was designed for the
enhanced delivery of biopharmaceuticals using coated titanium
microprojections [290]. This device allows a reproducible control
of skin penetration depth due to the incorporation of an applicator
device system. Moreover, the system was tested successfully for
ovalbumin delivery.
Microneedle rollers have been becoming commercially avail-
able during the last years. The MTS RollerTM (Fig. 18D) was
approved by the FDA for cosmetic purposes [9]. Clinical studies
showed that the use of this type of device is more effective than
other conventional ablative and non-ablative treatments in
stimulating the production of collagen and elastin to smooth
scars and erase wrinkles [269].
Valeritas developed two different types of MN-based device
[9]. The ﬁrst one was the Micro-TransTM Microneedle Array Patch
technology, a device that allows painless delivery drug delivery
into the dermis. The second one was the h-PatchTM, a subcutaneous
controlled drug delivery platform.
Another type of MN-based device that has been developed are
Micro-injection systems. These systems work in a similar way to
conventional syringes. Nanopass Technologies developed Micro-
nJet1, a hollow microneedle system for intradermal injection (Fig.
18G). This device is composed of four hollow silicon needles
shorter than 500 mm attached to a plastic device that can be
connected to any conventional syringe. This system was used to
deliver inﬂuenza vaccine, demonstrating at least equivalent
immunogenicity with only 20% of the dose used for conventional
vaccination [9]. Micronjet1 received FDA clearance in 2010 [12]. A
similar approach was carried out by the Swiss company Debiotech.
They developed an injector system containing a single or multiple
silicon MNs called DebioJectTM [291]. It can be used to inject
100 mL in less than 2 and up to 500 mL in less than 5 s.
Additionally, Sanoﬁ Pasteur MSD Limited developed an intrader-
mal micro-injection system for inﬂuenza vaccine (Fig 18H). This
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pioneering system was called Intanza1 [9] and uses the Soluvia1
injector developed by BD technologies. This device contains
1.5 mm long hypodermic needle attached to a syringe injector.
At this time Soluvia1 and MicronJet1 are the only MN-based
medical systems available on the market for therapeutic applica-
tions. In addition to Intanza1, this injector is currently commer-
cialised worldwide as IDﬂu1 and Fluzone Intradermal1 [12]. A
cosmetic MN product available on the market was developed by
Rodan+Fields Dermatologists. It is a dissolving MN array contain-
ing hydrolyzed hyaluronic acid for cosmetic application [292]. This
product has been commercially available since October 2014.
The presence of the ﬁrst MN devices in the market will
undoubtedly encourage those working in this ﬁeld to move
forward to up-scaling manufacturing and marketing. Additionally,
it serves to expand MN research, leading to the development of
more varied and far-reaching MN products.
5.2.6. Microneedle in clinical trials
As can be seen in Table 2 to date, there have been a wide variety
of completed clinical trials involving the use of MNs. All these trials
are mainly focused on the following main topics: Inﬂuenza vaccine,
delivery of insulin, delivery of parathyroid hormone, delivery of
anaesthetics and dermabrasion. Dermabrasion has been described
previously in Section 5.1.4.
Inﬂuenza intradermal vaccination has been extensively studied,
due to the constant demand for a seasonal vaccine that is easy and
safe to administer. The Soluvia1 microinjection system has
undergone extensive trials conducted around the world in
thousands of volunteers. In a randomised, open-label Phase II
clinical trial (978 healthy adults), the Soluvia1 system showed
equivalent (and superior in some cases) immune response to the
IM vaccine [293]. This study was followed by a Phase III
randomised, double-blind trial (2255 healthy adults), showing
that the novel vaccine system and the IM vaccine induced similar
post-vaccination antibody titres at 21 days post-immunisation
[294]. Additionally, Phase II and Phase III clinical trials were
conducted successfully to evaluate efﬁcacy in elderly individuals
(aged 60 years and older) [295]. Finally, a Phase II trial was
conducted to examine the beneﬁts in high-risk immunocompro-
mised patients. For this purpose, 62 renal-transplant patients
Fig. 18. Current microneedle devices. (A) Microstructured Transdermal System, (B) Microinfusor, (C) Macroﬂux1, (D) MTS RollerTM, (E) Micro-transTM, (F) h-patchTM, (G)
MicronJet, (H) Intanza1.
Source: Reproduced with permission of: [9].
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(non-responders to conventional inﬂuenza vaccination) were
randomised to receive ID and IM inﬂuenza vaccine. The results
of this trial showed that the volunteers presented better immune
responses when vaccinated ID. In addition to Soluvia1, the
MicronJet1 system has been studied for inﬂuenza vaccination
(180 healthy adults), showing similar immunogenic responses to
full-dose IM vaccination using lower doses.
The delivery of insulin using MN may be associated with
increased patient compliance when compared with traditional
subcutaneous injections. BD Technologies infusion system was
tested in humans (10 healthy adults) for the delivery of a 10-IU
standardised insulin lispro using stainless steel MNs of three
different lengths (1.25, 1.50 and 1.75 mm) [296,297]. Alternative
studies evaluated the pharmacokinetics and pharmacodynamics of
insulin after administration to type 1 diabetes patients using
different types of MNs [78,298]. The results of these studies have
been consistent and demonstrated that the use of MN enables
faster insulin uptake and equivalent bioavailability/blood-glucose
effects when compared with subcutaneous administrations.
Another study evaluated the patient preference of h-Patch over
conventional needle and syringe systems as insulin administration
devices (http://clinicaltrialsfeeds.org/clinical-trials/show/
NCT00453934).
The Macroﬂux1 device, originally developed by Alza, was
conducted through Phase I and II clinical trials by Zosano Pharma
for the delivery of parathyroid hormone to post-menopausal
women [225]. The study was performed using 165 postmenopausal
woman aged 50–81, whose last menstrual period was at least
1 year earlier. Volunteers were recruited in 13 centres in 3 different
countries. The use of the Macroﬂux1 device led to an increase in
the total hip bone mineral density when compared to the placebo
device and the commercial injection. These results, in combination
with the positive feedback obtained in focus groups suggest that an
upcoming Phase III study may well be successful. Focus groups
(288 post-menopausal women with osteoporosis; aged 60–85
years) highlighted that more than 90% of the patients like the patch
due to its ease of use. More than 80% of the interviewed patients
were capable of applying the patch correctly without assistance.
The delivery of lidocaine and other local anaesthetics using
solid and hollow MNs has been studied in several clinical trials. A
randomised single blind study (15 volunteers) was conducted to
compare time for anaesthesia onset and pain reduction after
administration of lidocaine via hollow 500 mm MNs versus
Mantoux injection with 26-Ga hypodermic needles [299]. Volun-
teers reported that MNs were less painful than hypodermic
needles. The anaesthetic effect of lidocaine was equivalent for both
Table 2
Completed clinical trials using MN.
Title Year Condition Phase Status
A study to assess the safety and efﬁcacy of a microneedle device
for local anaesthesia
2007 Local anaesthesia
Intradermal Injections
(MicronJet)
– Completed
A pilot study to evaluate the safety and immunogenicity of low
dose ﬂu vaccines (NANOVAX)
2007 Inﬂuenza – Completed
A pilot study to assess the safety, PK and PD of insulin injected via
MicronJet or conventional needle
2007 Intradermal injection Phase 0 Completed
Insulin delivery using microneedles in type 1 diabetes 2009 Type 1 diabetes mellitus Phase 2
Phase 3
Completed
Dose sparing intradermal S-OIV H1N1 inﬂuenza vaccination
device
2010 Inﬂuenza – Completed
Pharmacokinetics/dynamics of basal (continuous) insulin
infusion administered either intradermally or subcutaneously
2010 Diabetes mellitus, type 1
Diabetes mellitus, type 2
Phase 1
Phase 2
Completed
Tolerability study of the application of a 3M microstructure
transdermal system
2010 Healthy Phase 1 Completed
Optimisation of tuberculosis intradermal skin test 2011 Healthy Volunteers Phase 1 Completed
2010/2011 Trivalent inﬂuenza vaccination 2011 Inﬂuenza – Completed
ADRN inﬂuenza vaccine pilot 2011 Atopic dermatitis Phase 0 Completed
Comparison of 4 inﬂuenza vaccines in seniors (PCIRNRT09) 2011 Inﬂuenza vaccine Phase 4 Completed
Physiological study to determine the allergic skin activity after
different skin preparation
2012 Birch pollen allergy Phase 1 Completed
Phase 2 study of BA058 (abaloparatide) transdermal delivery in
postmenopausal women with osteoporosis
2012 Post-menopausal osteoporosis Phase 2 Completed
Multi-day (3) in-patient evaluation of intradermal versus
subcutaneous basal and bolus insulin infusion
2012 Type 1 diabetes Phase 1
Phase 2
Completed
Routes of immunisation and ﬂu immune responses (FLUWAY) 2012 Inﬂuenza Phase 1
Phase 2
Completed
intradermal versus intramuscular polio vaccine booster in HIV-
infected subjects (idipv)
2012 Polio immunity Phase 2 Completed
Intradermal trivalent inﬂuenza vaccine with imiquimod 2012 Chronic illness – Completed
Atopic dermatitis research network (ADRN) inﬂuenza vaccine
study
2012 Dermatitits
Atopic
– Completed
The use of microneedles in photodynamic therapy 2013 Actinic keratosis – Completed
Site selection for intracutaneous saline delivery 2013 Intracutaneous drug delivery – Completed
Intracutaneous delivery of varied dose volumes of saline 2013 Intracutaneous drug delivery – Completed
Safety study of suprachoroidal triamcinolone acetonide via
microneedle to treat uveitis
2013 Uveitis
Intermediate uveitis
Posterior uveitis
Panuveitis
Noninfectious uveitis
Phase 1
Phase 2
Completed
Immunogenicity of inactivated and live polio vaccines 2013 Poliomyelitis Phase 3 Completed
Comparison of mechanical penetration enhancers on metvixia
skin penetration
2015 Healthy Phase 1 Completed
Pretreatments of the skin prior to PDT 2015 Healthy Phase 1 Completed
Data obtained from https://clinicaltrials.gov/.
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injection methods. Another study evaluated the effectiveness of MN
arrays to facilitate the topical anaesthesia using a dyclonine cream
(25 healthy volunteers) [300]. The use of MN reduced the time to
meaningful pain reduction after a pain stimulus by a factor of 3.
It is noticeable that the number of MN clinical trials has
markedly increased during the last 5 years. This can be explained
mainly by the increasing interest in MN technology. Notably, the
majority of these trials involve the use of MN injection systems,
rather than MN array-based patches, and only a few conditions
have been studied. Therefore, during the next decade additional
clinical development will be required to prove the efﬁcacy and the
beneﬁt of MN delivery systems versus traditional delivery systems.
6. Conclusions
Transdermal drug delivery has historically been limited to only
those compounds that possess the appropriate physicochemical
properties, which allow for movement across the SC and into the
viable epidermis. The advancing nature of research into MN
delivery systems shows continual improvement in transdermal
delivery of therapeutics, which would otherwise never passively
cross the SC. The initial MN concept has developed beyond the
simplistic, solid MN design, into second and third generation
technologies, formulated from a range of materials, in varying
geometries and with diverse delivery briefs. The movement
towards enhancing transdermal delivery of larger peptide, protein
and vaccine components, as well as traditional molecules has led to
MN product development and regulation becoming of key
importance to researchers in this area. Clinical trials continue to
be discussed by various research centres globally, and with the
advent of Soluvia1 and MicronJet1, the arrival of commercially
available MN products is highly anticipated.
7. Expert opinion
Recent studies have shifted the original MN research paradigm
to a more patient focussed one, which moving forward is an
encouraging precedent. To proceed to the next step, we believe the
priority lies with the regulatory questions and patient concerns as
we examine what stands between our current MN knowledge and
the availability of a MN product for the patient. Human factors
concerning safety, efﬁcacy and usability appear to be the key.
Aligning engineering and product design, alongside the usability of
the device will ultimately lead to an optimised product and faster
progress through the relevant regulatory channels. The MN ﬁeld is
now at the stage where encompassing the end user in extensive
clinical trials is important, while simultaneously making the
necessary steps to scale up the production process.
A signiﬁcant barrier remaining to a MN product being available
relates to the regulation of MNs, primarily due to the innovative
nature of the technology. Will drug delivery via MNs be classed as
transdermal or intradermal? Will a MN patch be considered to be
more akin to an injection or a transdermal patch? Manufacturers
interested in the scale-up production of MNs await guidance
relating to pharmacopoeial standards and appropriate quality
control tests. Speciﬁc regulatory guidelines pertaining to patient
use are also needed, concerning factors such as packaging, disposal,
ease of use, assurance of correct use and also safety issues.
From a pharmaceutical viewpoint, it is evident that a number of
questions relating to patient use of MNs remain unanswered,
although it is noted that it may be some time until large population
surveillance can be conducted and suitable answers obtained to all.
Currently there are numerous studies which have involved human
volunteers, both with placebo MNs and drug-loaded MNs. These
investigations have formed the basis of an initial short-term safety
proﬁle, yielding promising results to date. The next step to
contemplate is the long-term safety of MN application; from both
the perspective of intermittent use and also of repeated applica-
tion, for example when considering the number of doses required
for insulin administration over a sustained period.
An example of a long-term issue worth further consideration is
that of polymer deposition in the skin following MN removal. This
is particularly likely to be of concern with dissolving MNs,
suggesting that a dissolving MN platform is more suitable for ‘‘one-
off’’ delivery, such as vaccination. If the deposited MN material is
not efﬁciently removed and metabolised by the body, an as yet
uncharacterised process; it is theorised that repeated application
of this type of MN could lead to distribution and deposition of
polymer throughout the body, hepatic accumulation and/or a
build-up of polymer in the dermal tissue. The possibility of an
immunological reaction is also worth noting, induced potentially
by the barrier disruption caused upon MN insertion, thus
stimulating the rich immune cell population of the skin.
Moving on from long-term safety to the patient use of the device,
the pharmacist or healthcare provider would need to be convinced of
the ability of the patient to use the device in their own home. Recent
studies, as discussed previously, have provided some convincing
evidence as to the validity of self-application. FDA draft guidance,
‘Applying Human Factors and Usability Engineering to Optimise
Medical Device Design,’ stresses the importance of an easy-to-use
device, with reduced need for training and reduced reliance on a user
manual. Emphasis is also placed on the requirement for evidence to
prove successful use of the device with minimal chance of error prior
to marketing. It is thought manual application using only thumb
pressure would be the preferred method of administration to
maximise patient ease of us. In order to capitalise on preconceived
positive beliefs relating to transdermal patches, MN patches must be
viewed in the same way by both prescriber and patient, as a
convenient alternative to oral and parenteral delivery. Furthermore,
if used as a tool to increase medication adherence, MNs will have
their greatest beneﬁt if their application is a straightforward one-
step process, with no additional devices.
MN knowledge has increased rapidly in recent years from the
description of the ﬁrst concept in 1976 to the present day, with a
plethora of MN designs currently described, delivering a wide
range of substrates. The bid to move towards MN commercia-
lisation can only intensify as the research questions highlighted
herein continue to be answered, in tandem with the publication
of further studies, outlining the increased delivery capacities of
MNs, with the ultimate endpoint of direct patient application.
MN devices have the capacity to play a role in modern
healthcare and, therefore it is now the researchers’ role to
ensure the present work is capitalised on and subsequently
translates into patient beneﬁt.
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